Walmart viagra price 2020

7 September 2020 The four day digital event will feature content aimed at all IBMS members walmart viagra price 2020 and will be free to attend SAVE THE DATE - 16-19th NovemberOur new, virtual CPD event, The Biomedical Scientist Live, will feature a packed line up of knowledge sharing sessions including. Workshops, seminars, discussions and demonstrations. The dedicated event website will be live soon and will include more information on how to sign up, free for IBMS members, and the programme of talks.

Members will be notified once live.1 September 2020 This September we're asking you to send us your best laboratory bloopers Our members work long hours and everything they do has to be 100% correct - so sometimes the slack falls out of their mouths. We got the idea for this competition courtesy of Gayatri Chohan who overheard walmart viagra price 2020 the line in the image when one of her colleagues answered the phone (and was overdue a holiday). What has come out of your mouth in the lab?.

Keep it family-friendly scientists!. The rules of the competition are simple:One entry per person (we will add your blooper to a randomly selected photo from our Biomedical Science Day archives - unless you want to send us your own photo)Use the #IBMSCompetition or #LaboratoryLaughs hashtag on Facebook, Twitter or Instagram along with your entry or email to website@ibms.orgThe competition starts Tuesday 1st September and closes at 12pm on Friday 18th SeptemberTwo entries will be chosen for the semi-finals and presented to our members in a social media poll on the week of 21th - 25th SeptemberThe winner will be announced at the end of the month and sent some goodies when we return to our officesOnce we get some entries, we will start a Facebook gallery so that you can see the all the bloopers in one place by clicking here..

Viagra risks

Viagra
Viagra plus
Intagra
Cialis
USA pharmacy price
130mg
Yes
40mg
Where to get
Indian Pharmacy
Yes
RX pharmacy
Online Pharmacy
Price per pill
Ask your Doctor
Ask your Doctor
Yes
Ask your Doctor
Brand
14h
24h
20h
21h
Male dosage
50mg 10 tablet $19.95
$
100mg 20 tablet $59.95
80mg 10 tablet $54.95
Pack price
Yes
Yes
Ask your Doctor
You need consultation

The World Health Organization (WHO) today listed the Comirnaty erectile dysfunction treatment mRNA treatment for emergency use, making the Pfizer/BioNTech treatment the first to receive emergency validation from WHO since the outbreak began a year ago.The WHO’s Emergency http://emukconsultancy.co.uk/cialis-generic-discountbuy-cialis-online Use Listing (EUL) opens viagra risks the door for countries to expedite their own regulatory approval processes to import and administer the treatment. It also enables UNICEF and the Pan-American Health Organization to procure the treatment for distribution to countries in need.“This is a very positive step towards ensuring global access to erectile dysfunction treatments. But I want to emphasize the need for an even greater global effort to achieve enough treatment supply to meet the needs of priority populations everywhere,” said Dr Mariângela Simão, viagra risks WHO Assistant-Director General for Access to Medicines and Health Products.

€œWHO and our partners are working night and day to evaluate other treatments that have reached safety and efficacy standards. We encourage even more developers to come forward for review and assessment. It’s vitally important that we secure the critical supply needed to serve all countries around the world and stem the viagra.” Regulatory experts convened by WHO from around the world and WHO’s own teams reviewed the data on the Pfizer/BioNTech viagra risks treatment’s safety, efficacy and quality as part of a risk-versus-benefit analysis.

The review found that the treatment met the must-have criteria for safety and efficacy set out by WHO, and that the benefits of using the treatment to address erectile dysfunction treatment offset potential risks.The treatment is also under policy review. WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) will convene on 5 January, 2021, to viagra risks formulate treatment specific policies and recommendations for this product’s use in populations, drawing from the SAGE population prioritization recommendations for erectile dysfunction treatments in general, issued in September 2020.The Comirnaty treatment requires storage using an ua-cold chain. It needs to be stored at -60°C to -90°C degrees.

This requirement makes the treatment more challenging to deploy in settings where ua-cold chain equipment may not be available or reliably accessible. For that reason, WHO is working to support countries in assessing their delivery plans and preparing for use where possible.How the emergency use listing worksThe emergency use listing (EUL) procedure assesses the suitability of novel viagra risks health products during public health emergencies. The objective is to make medicines, treatments and diagnostics available as rapidly as possible to address the emergency while adhering to stringent criteria of safety, efficacy and quality.

The assessment weighs the threat posed by the emergency as well as the benefit that would accrue from the use of the product against any potential risks.The EUL pathway involves a rigorous assessment of late phase II and phase III clinical trial data as well as substantial additional data on safety, efficacy, quality and a risk management plan. These data are reviewed by independent experts and WHO teams who consider the current body of evidence on the treatment under consideration, the viagra risks plans for monitoring its use, and plans for further studies.Experts from individual national authorities are invited to participate in the EUL review. Once a treatment has been listed for WHO emergency use, WHO engages its regional regulatory networks and partners to inform national health authorities on the treatment and its anticipated benefits based on data from clinical studies to date.In addition to the global, regional, and country regulatory procedures for emergency use, each country undertakes a policy process to decide whether and in whom to use the treatment, with prioritization specified for the earliest use.

Countries also undertake a treatment readiness assessment which informs the treatment deployment and viagra risks introduction plan for the implementation of the treatment under the EUL.As part of the EUL process, the company producing the treatment must commit to continue to generate data to enable full licensure and WHO prequalification of the treatment. The WHO prequalification process will assess additional clinical data generated from treatment trials and deployment on a rolling basis to ensure the treatment meets the necessary standards of quality, safety and efficacy for broader availability.More information:[embedded content]Dr Tedros Adhanom Ghebreyesus, WHO Director-GeneralAs people around the world celebrated New Year's Eve 12 months ago, a new global threat emerged. Since that moment, the erectile dysfunction treatment viagra has taken so many lives and caused massive disruption to families, societies and economies all over the world.

But it also triggered the fastest and most wide-reaching response to a global health viagra risks emergency in human history. The hallmarks of this response have been an unparalleled mobilization of science, a search for solutions and a commitment to global solidarity. Acts of generosity, large and small, equipped viagra risks hospitals with the tools that health workers needed to stay safe and care for their patients.

Outpourings of kindness have helped society’s most vulnerable through troubled times. treatments, therapeutics and diagnostics have been developed and rolled out, at record speed, thanks to collaborations including the Access to erectile dysfunction treatment Tools Accelerator. Equity is the essence of the ACT Accelerator, and its treatment viagra risks arm, COVAX, which has secured access to 2 billion doses of promising treatment candidates.

treatments offer great hope to turn the tide of the viagra. But to protect the world, we must ensure that all people at risk everywhere – not just in countries who can afford treatments – are immunized. To do this, COVAX needs just over 4 billion US dollars urgently to buy treatments for low- and lower-middle income countries viagra risks.

This is the challenge we must rise to in the new year. My brothers and sisters, the events of 2020 have provided telling lessons, and reminders, for us viagra risks all to take into 2021. First and foremost, 2020 has shown that governments must increase investment in public health, from funding access to erectile dysfunction treatments for all people, to making our systems better prepared to prevent and respond to the next, inevitable, viagra.

At the heart of this is investing in universal health coverage to make health for all a reality. Second, as it will take time to vaccinate everyone against erectile dysfunction treatment, we must keep adhering to tried and tested measures that viagra risks keep each and all of us safe. This means maintaining physical distance, wearing face masks, practicing hand and respiratory hygiene, avoiding crowded indoor places and meeting people outside.

These simple, yet effective measures will save lives and reduce the suffering that so many people viagra risks encountered in 2020. Third, and above all, we must commit to working together in solidarity, as a global community, to promote and protect health today, and in the future. We have seen how divisions in politics and communities feed the viagra and foment the crisis.

But collaboration and partnership viagra risks save lives and safeguard societies. In 2020, a health crisis of historic proportions showed us just how closely connected we all are. We saw how acts of kindness and care helped neighbors through times of great struggle.

But we viagra risks also witnessed how acts of malice, and misinformation, caused avoidable harm. Going into 2021, we have a simple, yet profound, choice to make. Do we ignore the lessons of 2020 and allow insular, partisan approaches, conspiracy theories and attacks on science to prevail, resulting in unnecessary suffering viagra risks to people’s health and society at large?.

Or do we walk the last miles of this crisis together, helping each other along the way, from sharing treatments fairly, to offering accurate advice, compassion and care to all who need, as one global family. The choice is easy. There is light at the end viagra risks of the tunnel, and we will get there by taking the path together.

WHO stands with you – We Are Family and we are In This Together. I wish you and your loved ones a peaceful, safe and healthy new year..

The World Health Organization (WHO) today listed the Comirnaty erectile dysfunction treatment mRNA treatment for emergency use, making the walmart viagra price 2020 Pfizer/BioNTech treatment the first to receive emergency validation from WHO since the outbreak began a year ago.The WHO’s Emergency Use Listing (EUL) opens the door for countries to expedite their own regulatory approval processes to import and administer the treatment. It also enables UNICEF and the Pan-American Health Organization to procure the treatment for distribution to countries in need.“This is a very positive step towards ensuring global access to erectile dysfunction treatments. But I want to emphasize the need for an even greater global effort to achieve enough treatment supply to meet the needs of priority populations everywhere,” said Dr Mariângela Simão, WHO Assistant-Director walmart viagra price 2020 General for Access to Medicines and Health Products. €œWHO and our partners are working night and day to evaluate other treatments that have reached safety and efficacy standards. We encourage even more developers to come forward for review and assessment.

It’s vitally important walmart viagra price 2020 that we secure the critical supply needed to serve all countries around the world and stem the viagra.” Regulatory experts convened by WHO from around the world and WHO’s own teams reviewed the data on the Pfizer/BioNTech treatment’s safety, efficacy and quality as part of a risk-versus-benefit analysis. The review found that the treatment met the must-have criteria for safety and efficacy set out by WHO, and that the benefits of using the treatment to address erectile dysfunction treatment offset potential risks.The treatment is also under policy review. WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) will convene on 5 January, 2021, to formulate treatment specific policies and recommendations for this product’s use in populations, drawing from the SAGE population prioritization recommendations for erectile dysfunction treatments in general, issued in walmart viagra price 2020 September 2020.The Comirnaty treatment requires storage using an ua-cold chain. It needs to be stored at -60°C to -90°C degrees. This requirement makes the treatment more challenging to deploy in settings where ua-cold chain equipment may not be available or reliably accessible.

For that reason, WHO is working to support countries in assessing their delivery plans and preparing for use where possible.How the emergency use listing worksThe emergency use listing (EUL) procedure assesses the suitability of novel health products during walmart viagra price 2020 public health emergencies. The objective is to make medicines, treatments and diagnostics available as rapidly as possible to address the emergency while adhering to stringent criteria of safety, efficacy and quality. The assessment weighs the threat posed by the emergency as well as the benefit that would accrue from the use of the product against any potential risks.The EUL pathway involves a rigorous assessment of late phase II and phase III clinical trial data as well as substantial additional data on safety, efficacy, quality and a risk management plan. These data are reviewed by independent experts and WHO teams who consider the current body of evidence on the treatment under consideration, the plans for monitoring its use, and plans for further studies.Experts from individual national walmart viagra price 2020 authorities are invited to participate in the EUL review. Once a treatment has been listed for WHO emergency use, WHO engages its regional regulatory networks and partners to inform national health authorities on the treatment and its anticipated benefits based on data from clinical studies to date.In addition to the global, regional, and country regulatory procedures for emergency use, each country undertakes a policy process to decide whether and in whom to use the treatment, with prioritization specified for the earliest use.

Countries also undertake a treatment walmart viagra price 2020 readiness assessment which informs the treatment deployment and introduction plan for the implementation of the treatment under the EUL.As part of the EUL process, the company producing the treatment must commit to continue to generate data to enable full licensure and WHO prequalification of the treatment. The WHO prequalification process will assess additional clinical data generated from treatment trials and deployment on a rolling basis to ensure the treatment meets the necessary standards of quality, safety and efficacy for broader availability.More information:[embedded content]Dr Tedros Adhanom Ghebreyesus, WHO Director-GeneralAs people around the world celebrated New Year's Eve 12 months ago, a new global threat emerged. Since that moment, the erectile dysfunction treatment viagra has taken so many lives and caused massive disruption to families, societies and economies all over the world. But it also triggered the fastest and walmart viagra price 2020 most wide-reaching response to a global health emergency in human history. The hallmarks of this response have been an unparalleled mobilization of science, a search for solutions and a commitment to global solidarity.

Acts of generosity, large and small, equipped hospitals with the tools that health workers needed to stay safe walmart viagra price 2020 and care for their patients. Outpourings of kindness have helped society’s most vulnerable through troubled times. treatments, therapeutics and diagnostics have been developed and rolled out, at record speed, thanks to collaborations including the Access to erectile dysfunction treatment Tools Accelerator. Equity is the essence of the ACT Accelerator, and its treatment arm, COVAX, which has secured access to 2 billion doses of walmart viagra price 2020 promising treatment candidates. treatments offer great hope to turn the tide of the viagra.

But to protect the world, we must ensure that all people at risk everywhere – not just in countries who can afford treatments – are immunized. To do this, walmart viagra price 2020 COVAX needs just over 4 billion US dollars urgently to buy treatments for low- and lower-middle income countries. This is the challenge we must rise to in the new year. My brothers and sisters, the events of 2020 have provided telling lessons, and walmart viagra price 2020 reminders, for us all to take into 2021. First and foremost, 2020 has shown that governments must increase investment in public health, from funding access to erectile dysfunction treatments for all people, to making our systems better prepared to prevent and respond to the next, inevitable, viagra.

At the heart of this is investing in universal health coverage to make health for all a reality. Second, as it will walmart viagra price 2020 take time to vaccinate everyone against erectile dysfunction treatment, we must keep adhering to tried and tested measures that keep each and all of us safe. This means maintaining physical distance, wearing face masks, practicing hand and respiratory hygiene, avoiding crowded indoor places and meeting people outside. These simple, yet effective walmart viagra price 2020 measures will save lives and reduce the suffering that so many people encountered in 2020. Third, and above all, we must commit to working together in solidarity, as a global community, to promote and protect health today, and in the future.

We have seen how divisions in politics and communities feed the viagra and foment the crisis. But collaboration and partnership walmart viagra price 2020 save lives and safeguard societies. In 2020, a health crisis of historic proportions showed us just how closely connected we all are. We saw how acts of kindness and care helped neighbors through times of great struggle. But we also witnessed how acts of walmart viagra price 2020 malice, and misinformation, caused avoidable harm.

Going into 2021, we have a simple, yet profound, choice to make. Do we ignore the lessons of 2020 and allow insular, partisan approaches, conspiracy theories and attacks on science to prevail, resulting in unnecessary suffering to people’s health and society walmart viagra price 2020 at large?. Or do we walk the last miles of this crisis together, helping each other along the way, from sharing treatments fairly, to offering accurate advice, compassion and care to all who need, as one global family. The choice is easy. There is light at walmart viagra price 2020 the end of the tunnel, and we will get there by taking the path together.

WHO stands with you – We Are Family and we are In This Together. I wish you and your loved ones a peaceful, safe and healthy new year..

How should I take Viagra?

Take Viagra by mouth with a glass of water. The dose is usually taken 1 hour before sexual activity. You should not take the dose more than once per day. Do not take your medicine more often than directed. Overdosage: If you think you have taken too much of Viagra contact a poison control center or emergency room at once. NOTE: Viagra is only for you. Do not share Viagra with others.

Red viagra pill

Building support for a congressional bill to take on China, Commerce Secretary Gina Raimondo said yesterday that automakers’ grand electric vehicle red viagra pill plans are imperiled by the ongoing shortage of computer semiconductors. €œThe average electric vehicle has about 2,000 chips, roughly double the average number of chips in a non-electric car,” Raimondo said in prepared remarks to the Detroit Economic Club, a nonprofit business group located in Michigan’s automotive hub. €œAs companies like Ford and GM compete to grab a foothold in the electric vehicle market, we know that innovation in red viagra pill the American battery market will be stifled if we aren’t also investing in domestic semiconductor innovation at the same time,” Raimondo said. Prior to the speech, Raimondo also told reporters that Biden’s plans for half of new vehicles to be electric by 2030 depends on the U.S. Investing in semiconductor production.

€œThat’s necessary for our American economic competitiveness, it’s necessary if we’re going to meet our climate change goals, and it’s necessary to create jobs,” she told The Detroit News red viagra pill. The secretary’s Michigan visit was intended to drum up support for a $52 billion legislative package to revitalize the U.S. Semiconductor industry. The “Creating Helpful Incentives to Produce Semiconductors (CHIPS) for America Act,” or “CHIPS for America Act” in short, was passed by the Senate in June as part of a bigger bill but hasn’t received red viagra pill a vote in the House of Representatives. The globe’s semiconductors are mainly made in Asia, especially China and Taiwan.

As viagra lockdowns eased and the economy coughed back to life, red viagra pill automakers have been frustrated in their efforts to meet pent-up demand for cars. Semiconductor companies prioritized electronics companies, not automakers, for their limited supplies. As a result, nearly every automaker has experienced chip-related slowdowns and shutdowns. The shortages have already tapped the brakes on red viagra pill several high-profile EVs. In August, Ford Motor Co.

Told customers that a lack of chips would put off delivery of its flagship EV, the Mustang Mach-E, for several weeks, and General Motors Co. Temporarily shut the Detroit red viagra pill factory where it makes the Bolt EV. Also this summer, Rivian Automotive Inc., the electric truck-maker, cited semiconductors as the reason for a delay, and its output remains very slow. A spokesperson for the Commerce Department said that the figure Raimondo cited—that red viagra pill an EV has twice the chips a traditional car has—came from discussions with automakers. €œWe believe it’s a reasonable average,” the spokesperson said.

A recent study by IDTechEx, a consultancy based in the United Kingdom, estimated that an EV requires more than twice as many semiconductors as its internal-combustion-engine counterpart, mainly because the EV demands much more use of power electronics. An analyst said that Raimondo is correct that EVs require more semiconductors but red viagra pill didn’t necessarily agree that it means electric vehicles are uniquely vulnerable to shortages of them. €œEVs, particularly those designed on EV-only platforms, generally have more electronic content, and thus require more chips,” said Alan Baum, an automotive forecaster based in Michigan who studies electric vehicles. However, he added, “design of EVs matter and ... A clean sheet approach, like Tesla, or even new platforms from GM, Ford and VW allow for greater capability and more red viagra pill efficient use of chips.” Tesla Inc., the electric automaker, has faced fewer chip-related production problems.

Baum said that Tesla’s design requires less chips because it “has centralized computing in a single spot in the car, rather than computing spread through the various vehicle systems.” Tesla’s rivals have taken action on chip shortages by incorporating themselves into the supply chain. Earlier this month, Ford struck red viagra pill an agreement with maker GlobalFoundries to make chips, and GM said it would work with Qualcomm Inc. And NXP Semiconductors NV in a similar arrangement. Reprinted from E&E News with permission from POLITICO, LLC. Copyright 2021 red viagra pill.

E&E News provides essential news for energy and environment professionals.The past few days have been awash with news of the emergence of the latest concerning variant of the viagra behind erectile dysfunction treatment, which the World Health Organization has dubbed Omicron. Scientists detected this new variant through genomic surveillance in South Africa, but in a quickly evolving viagra we still don’t know where it originated, and we still don’t know how important Omicron will be. I am a global red viagra pill health scientist, with a background in public health research and infectious disease epidemiology. I believe this new variant is a consequence of treatment inequity in parts of Africa, where the vaccination coverage in many countries is less than 10 percent. One of the consequences of uncontrolled outbreaks has been an red viagra pill increased risk of new erectile dysfunction variants of concern.

We have seen this in the U.K., where the Alpha variant was first detected while treatments were still early in deployment and the vaccination rate was low. And one consequence of the humanitarian emergency in India in early 2021 was the emergence of the Delta variant. A strong vaccination rate can reduce transmission and red viagra pill thus stop outbreaks. But only if people have access to the products. In my field, many people have thought that richer countries grabbing the treatment supply would inevitably come back to bite us on our backsides at some point.

Omicron looks to be the variant with red viagra pill sharp teeth. Only time will tell how dangerous Omicron will be, but inequitable access to treatments means this scenario could keep happening. Until erectile dysfunction treatment is conquered everywhere, it can be red viagra pill reintroduced anywhere. The main focus of my international research is West Africa, particularly Ghana and Togo, with ongoing projects around the viagra response and erectile dysfunction treatment hesitancy. I wrote back in July 2020 that, to coin a British phrase, there’s no “I’m alright, Jack” about this for those of us in higher-income settings.

Eighteen months red viagra pill on, erectile dysfunction treatment very much remains an issue for us all. The international picture around treatment distribution and uptake is stark, with the “haves” and “have nots” geographically obvious. Only around 11 percent of people on the African continent have received even one dose of a erectile dysfunction treatment. Approximately red viagra pill 7 percent are considered fully vaccinated. Compare that with South America and Asia, where 72 percent and 63 percent respectively have received at least one dose.

Despite the low treatment rates and limited public health resources, I’d red viagra pill argue much of sub-Saharan Africa has done very well at keeping outbreaks under control. For example, in Ghana, the Delta variant arrived in July 2021 based on sequencing data, and there was community transmission. Yet, the Ghana Health Service and public health teams have managed to control that outbreak, a feat that many richer countries have repeatedly failed to manage. However, there is a highly susceptible population across red viagra pill Africa without any immunity from vaccination or prior . We see from the evidence base that erectile dysfunction treatments reduce rates of new s and onward transmission There is some early speculation from virologists that Omicron emerged from a person chronically infected with erectile dysfunction, and that the index case was in an area of poor genomic surveillance outside of South Africa.

It is harder to identify new variants in near real time if there is an overall lack of genomic infrastructure and expertise. Other countries in Southern Africa have observed cases of red viagra pill Omicron. This includes Botswana, which weathered an uncontrolled outbreak in August 2021. There was a big spike in cases and a positive test rate of more than 50 red viagra pill percent. This is a high percentage, and with so many positive cases in those tested, it is very likely there were many more cases in circulation that weren’t picked up by the testing program.

Getting more people vaccinated in countries where the rate has been low is key to stopping the next variant. The problems in resolving treatment red viagra pill inequity are wide and varied. They include increasing the supply in resource-poor areas, and not just treatments that have been “generously donated” just as they are about to expire. What we do here in the Global North is observed and absorbed in the Global South. When health workers do arrive in communities armed with red viagra pill immunizations, the people there need to be willing to be immunized.

Our research in Ghana has shown that willingness to vaccinate varies over time, but was at 71 percent in June 2021, down from 82 percent from our previous survey in April. Where individuals expressed hesitancy, a common reason was to make reference to the inconsistent approaches to use of the Oxford AstraZeneca treatment in the Global North red viagra pill. Specific comments often focused on the reactions to the blood clots as possible adverse events. To quote one of our participants. €œWhy would I red viagra pill want that damaged white-man product?.

€ News travels fast and easily in a globalized world. Then there are the conversations around waivers on treatment patents. Granting these waivers has long been discussed during the viagra, but therein lies the issue red viagra pill. On November 25, Ngozi Okonjo-Iweala, the head of the World Trade Organization, described the protracted negotiations as “stuck.” There are agreements in place for some level of treatment manufacturing in South Africa, albeit at the end stage of the process, which is termed “fill and finish.” Many companies based in India, Thailand and South Africa have the potential to develop their own mRNA treatments, described by Tom Frieden, the former director of the Centers for Disease Control and Prevention in the United States, as “our insurance policy against variants and production failure.” But these are all still works in progress, and in the meantime, Omicron spreads, and what comes after it is surely percolating in areas of low vaccination rates. We don’t yet know how severe Omicron will be in unvaccinated red viagra pill populations, or the extent and severity of breakthrough s.

There is little known about its transmissibility, or whether it is likely to outcompete Delta and become established as the most common type of erectile dysfunction variant. These are all important questions that a global thirst for knowledge will seek to answer over the coming weeks. But why wait for those red viagra pill answers?. We need the richer countries and other key stakeholders to go beyond mere platitudes and actually deliver on their commitments to share doses. A variant can emerge anywhere, but we can minimize the chances of an outbreak and therefore reduce likelihood of notable new viagra mutations and the need to learn another letter of the Greek alphabet.

How long do us rich folk want the red viagra pill viagra to continue?. Some people may consider that we are done with this novel erectile dysfunction. However, it’s very clear that the erectile dysfunction is nowhere near done with us..

Building support for a congressional bill to take on China, Commerce Secretary Gina Raimondo said yesterday that automakers’ grand electric walmart viagra price 2020 vehicle plans are imperiled by the ongoing shortage of computer semiconductors. €œThe average electric vehicle has about 2,000 chips, roughly double the average number of chips in a non-electric car,” Raimondo said in prepared remarks to the Detroit Economic Club, a nonprofit business group located in Michigan’s automotive hub. €œAs companies like Ford and GM walmart viagra price 2020 compete to grab a foothold in the electric vehicle market, we know that innovation in the American battery market will be stifled if we aren’t also investing in domestic semiconductor innovation at the same time,” Raimondo said. Prior to the speech, Raimondo also told reporters that Biden’s plans for half of new vehicles to be electric by 2030 depends on the U.S.

Investing in semiconductor production. €œThat’s necessary for our American economic competitiveness, it’s necessary if we’re going to meet our climate change goals, and it’s necessary to create jobs,” she told The Detroit walmart viagra price 2020 News. The secretary’s Michigan visit was intended to drum up support for a $52 billion legislative package to revitalize the U.S. Semiconductor industry.

The “Creating Helpful Incentives to Produce Semiconductors (CHIPS) for America Act,” or “CHIPS for America Act” in short, was passed by the Senate in June as part of a bigger bill but hasn’t received a vote in the House of walmart viagra price 2020 Representatives. The globe’s semiconductors are mainly made in Asia, especially China and Taiwan. As viagra lockdowns eased and the economy coughed back to walmart viagra price 2020 life, automakers have been frustrated in their efforts to meet pent-up demand for cars. Semiconductor companies prioritized electronics companies, not automakers, for their limited supplies.

As a result, nearly every automaker has experienced chip-related slowdowns and shutdowns. The shortages have walmart viagra price 2020 already tapped the brakes on several high-profile EVs. In August, Ford Motor Co. Told customers that a lack of chips would put off delivery of its flagship EV, the Mustang Mach-E, for several weeks, and General Motors Co.

Temporarily shut the walmart viagra price 2020 Detroit factory where it makes the Bolt EV. Also this summer, Rivian Automotive Inc., the electric truck-maker, cited semiconductors as the reason for a delay, and its output remains very slow. A spokesperson for the Commerce walmart viagra price 2020 Department said that the figure Raimondo cited—that an EV has twice the chips a traditional car has—came from discussions with automakers. €œWe believe it’s a reasonable average,” the spokesperson said.

A recent study by IDTechEx, a consultancy based in the United Kingdom, estimated that an EV requires more than twice as many semiconductors as its internal-combustion-engine counterpart, mainly because the EV demands much more use of power electronics. An analyst said that Raimondo is correct that EVs require more semiconductors but didn’t necessarily agree that it means electric vehicles walmart viagra price 2020 are uniquely vulnerable to shortages of them. €œEVs, particularly those designed on EV-only platforms, generally have more electronic content, and thus require more chips,” said Alan Baum, an automotive forecaster based in Michigan who studies electric vehicles. However, he added, “design of EVs matter and ...

A clean sheet approach, like Tesla, or even new platforms from GM, Ford and VW allow for greater capability and more efficient use of chips.” Tesla Inc., the electric walmart viagra price 2020 automaker, has faced fewer chip-related production problems. Baum said that Tesla’s design requires less chips because it “has centralized computing in a single spot in the car, rather than computing spread through the various vehicle systems.” Tesla’s rivals have taken action on chip shortages by incorporating themselves into the supply chain. Earlier this month, Ford walmart viagra price 2020 struck an agreement with maker GlobalFoundries to make chips, and GM said it would work with Qualcomm Inc. And NXP Semiconductors NV in a similar arrangement.

Reprinted from E&E News with permission from POLITICO, LLC. Copyright 2021 walmart viagra price 2020. E&E News provides essential news for energy and environment professionals.The past few days have been awash with news of the emergence of the latest concerning variant of the viagra behind erectile dysfunction treatment, which the World Health Organization has dubbed Omicron. Scientists detected this new variant through genomic surveillance in South Africa, but in a quickly evolving viagra we still don’t know where it originated, and we still don’t know how important Omicron will be.

I am a global health scientist, with a walmart viagra price 2020 background in public health research and infectious disease epidemiology. I believe this new variant is a consequence of treatment inequity in parts of Africa, where the vaccination coverage in many countries is less than 10 percent. One of the consequences of uncontrolled outbreaks has been an increased risk of new walmart viagra price 2020 erectile dysfunction variants of concern. We have seen this in the U.K., where the Alpha variant was first detected while treatments were still early in deployment and the vaccination rate was low.

And one consequence of the humanitarian emergency in India in early 2021 was the emergence of the Delta variant. A strong vaccination rate can reduce transmission and thus walmart viagra price 2020 stop outbreaks. But only if people have access to the products. In my field, many people have thought that richer countries grabbing the treatment supply would inevitably come back to bite us on our backsides at some point.

Omicron looks walmart viagra price 2020 to be the variant with sharp teeth. Only time will tell how dangerous Omicron will be, but inequitable access to treatments means this scenario could keep happening. Until erectile dysfunction treatment walmart viagra price 2020 is conquered everywhere, it can be reintroduced anywhere. The main focus of my international research is West Africa, particularly Ghana and Togo, with ongoing projects around the viagra response and erectile dysfunction treatment hesitancy.

I wrote back in July 2020 that, to coin a British phrase, there’s no “I’m alright, Jack” about this for those of us in higher-income settings. Eighteen months on, erectile dysfunction treatment very much remains an issue walmart viagra price 2020 for us all. The international picture around treatment distribution and uptake is stark, with the “haves” and “have nots” geographically obvious. Only around 11 percent of people on the African continent have received even one dose of a erectile dysfunction treatment.

Approximately 7 walmart viagra price 2020 percent are considered fully vaccinated. Compare that with South America and Asia, where 72 percent and 63 percent respectively have received at least one dose. Despite the low treatment rates and limited public health resources, I’d argue much of sub-Saharan Africa has done very well walmart viagra price 2020 at keeping outbreaks under control. For example, in Ghana, the Delta variant arrived in July 2021 based on sequencing data, and there was community transmission.

Yet, the Ghana Health Service and public health teams have managed to control that outbreak, a feat that many richer countries have repeatedly failed to manage. However, there is a highly susceptible population across Africa without any immunity from vaccination or prior walmart viagra price 2020 . We see from the evidence base that erectile dysfunction treatments reduce rates of new s and onward transmission There is some early speculation from virologists that Omicron emerged from a person chronically infected with erectile dysfunction, and that the index case was in an area of poor genomic surveillance outside of South Africa. It is harder to identify new variants in near real time if there is an overall lack of genomic infrastructure and expertise.

Other countries in Southern Africa have observed cases of walmart viagra price 2020 Omicron. This includes Botswana, which weathered an uncontrolled outbreak in August 2021. There was a big spike in cases and a positive test rate of more than 50 walmart viagra price 2020 percent. This is a high percentage, and with so many positive cases in those tested, it is very likely there were many more cases in circulation that weren’t picked up by the testing program.

Getting more people vaccinated in countries where the rate has been low is key to stopping the next variant. The problems in resolving treatment inequity are wide and walmart viagra price 2020 varied. They include increasing the supply in resource-poor areas, and not just treatments that have been “generously donated” just as they are about to expire. What we do here in the Global North is observed and absorbed in the Global South.

When health walmart viagra price 2020 workers do arrive in communities armed with immunizations, the people there need to be willing to be immunized. Our research in Ghana has shown that willingness to vaccinate varies over time, but was at 71 percent in June 2021, down from 82 percent from our previous survey in April. Where individuals expressed hesitancy, a common reason was to make reference to the inconsistent approaches to use of the Oxford AstraZeneca walmart viagra price 2020 treatment in the Global North. Specific comments often focused on the reactions to the blood clots as possible adverse events.

To quote one of our participants. €œWhy would I want that damaged white-man walmart viagra price 2020 product?. € News travels fast and easily in a globalized world. Then there are the conversations around waivers on treatment patents.

Granting these waivers has long been discussed walmart viagra price 2020 during the viagra, but therein lies the issue. On November 25, Ngozi Okonjo-Iweala, the head of the World Trade Organization, described the protracted negotiations as “stuck.” There are agreements in place for some level of treatment manufacturing in South Africa, albeit at the end stage of the process, which is termed “fill and finish.” Many companies based in India, Thailand and South Africa have the potential to develop their own mRNA treatments, described by Tom Frieden, the former director of the Centers for Disease Control and Prevention in the United States, as “our insurance policy against variants and production failure.” But these are all still works in progress, and in the meantime, Omicron spreads, and what comes after it is surely percolating in areas of low vaccination rates. We don’t yet walmart viagra price 2020 know how severe Omicron will be in unvaccinated populations, or the extent and severity of breakthrough s. There is little known about its transmissibility, or whether it is likely to outcompete Delta and become established as the most common type of erectile dysfunction variant.

These are all important questions that a global thirst for knowledge will seek to answer over the coming weeks. But why walmart viagra price 2020 wait for those answers?. We need the richer countries and other key stakeholders to go beyond mere platitudes and actually deliver on their commitments to share doses. A variant can emerge anywhere, but we can minimize the chances of an outbreak and therefore reduce likelihood of notable new viagra mutations and the need to learn another letter of the Greek alphabet.

How long do us rich folk want the walmart viagra price 2020 viagra to continue?. Some people may consider that we are done with this novel erectile dysfunction. However, it’s very clear that the erectile dysfunction is nowhere near done with us..

Define viagra

As part of our ongoing commitment to prioritizing healing and humanity as we stand against social injustice, Mathematica is pleased to announce that President and CEO Paul Decker is joining more than 1,300 How much cipro cost CEOs and business leaders as a member of CEO Action for Diversity define viagra and Inclusion™. This coalition represents the largest CEO-driven business commitment to advancing workplace diversity, equity, and inclusion, while working to ensure opportunity at the highest levels of corporate leadership.“During a time when the nation continues to be tested by unresolved issues of social justice, Mathematica has taken significant strides toward centering diversity, equity, and inclusion in our interactions with each other and in our approach to our work,” said Decker. €œToday, we’re taking another important step forward by joining CEO Action for Diversity and Inclusion, an organization that unites business leaders from around the world to advance DEI initiatives in our define viagra own workplaces and beyond. I’m honored to represent Mathematica in this coalition fighting for meaningful change.”CEO Action represents approximately 13 million employees across more than 85 industries.

As a member through its CEO, Mathematica has committed to dedicating time and resources to advancing diversity, equity, and inclusion both within Mathematica and as part of the CEO Action network. Decker has also taken the CEO Action pledge to “check my bias, speak up for others and show up for all.”A 100% employee-owned company, Mathematica works with private- and public-sector agencies, corporations, and foundations around the world, using data and define viagra evidence to improve the lives of people and communities. About CEO Action for Diversity &. Inclusion™ CEO Action for Diversity &.

Inclusion™ is the largest define viagra CEO-driven business commitment to advance diversity and inclusion within the workplace. Bringing together more than 1,000 CEOs of America’s leading organizations, the commitment outlines actions that participating companies pledge to take to cultivate a workplace where diverse perspectives and experiences are welcomed and respected, employees feel comfortable and encouraged to discuss diversity and inclusion, and where best known—and successful—actions can be shared across organizations. Learn more at CEOAction.com and connect with them on Twitter. @CEOAction.

For more information, please contact:Jennifer de Vallancejdevallance@mathematica-mpr.com202-484-4692Mathematica is committed to advancing public health by applying our expertise across disciplines that constitute some of the most critical areas of public health today. The following focus areas highlight how we’re working to progress together to improve public well-being.APHA Public Health Film Festival. Helping Families Affected by Substance UseThe APHA selected a short film that Mathematica produced with support from the Administration for Children and Families to show at the APHA Public Health Film Festival. The film focuses on how the Regional Partnership Grant program improves the safety, permanency, and well-being of children affected by parent’s substance use disorders.

Starting October 19, registered APHA Annual Meeting attendees can watch the film on demand. Registered attendees can also submit questions to Debra Strong a senior researcher for the Regional Partnership Grant National Cross-Site Evaluation, using a discussion board that will be available with the film. Please visit APHA’s page about public health films focusing on substance use and addiction treatment for more information. Diversity, Equity, and InclusionWhat does it take for organizations to progress together?.

It takes a common purpose, shared values, a complementary array of resources and capabilities, and a mutual desire to learn from and with each other. Our ongoing diversity, equity, and inclusion journey is driving necessary changes in who we are. How we relate to each other, our partners, and our communities. And how we approach our work.

Social Determinants of HealthPolicymakers and practitioners are increasingly interested in social determinants of health—the conditions in which people are born, grow, live, work, and age—to address upstream social risks, such as food insecurity and lack of affordable housing, that, in turn, improve health care outcomes. Mathematica data and policy experts recently produced a series of blog posts and research on how different stakeholders can improve and leverage data on social determinants of health to maximize the health and well-being of children and adults in the United States.erectile dysfunction treatment ServicesResponding to the current public health crisis and illuminating the path forward to safely re-open businesses, schools, workplaces, and community services requires a seasoned partner with trusted solutions. Built on our foundation of rigorous data and evidence, Mathematica’s scalable services provide state and local agencies, as well as private-sector employers, with the confidence and clarity they need to take on the complex challenges of erectile dysfunction treatment. Some of our services include contact tracing, workforce planning, modeling and forecasting, and wastewater testing and analysis.Data Analytics and Survey ExpertiseAt Mathematica, we apply our expertise at the intersection of data science and social science to produce efficient, high quality, and action-oriented analysis that advances your mission.Using advanced technologies, reusable and scalable platforms, and high-performance secure cloud infrastructure, we enable our partners to target areas of opportunity and make the most of their data.

We collect the data you need, manage data as a secure asset, analyze to surface insights, and place this knowledge in the hands of those who need it most.Mental Health and Substance UseMathematica understands the pressing challenges faced by our partners working to improve the delivery system, innovative value-based service models, and financing strategies that states and payers are testing—strategies that could improve the prevention and treatment of behavioral health conditions. We’re leading efforts to address the opioid crisis, increase access to care while controlling costs, and support the integration of behavioral health services with other health care and social services.Our staff have in-depth knowledge of the complex array of intersecting public and private programs and eligibility requirements that create challenges for consumers to get the help they need. Our work involves evaluating a wide range of behavioral health service delivery and payment models, helping partners establish programs that implement new services and policies and fill data gaps, fielding large-scale behavioral health surveys, developing and implementing behavioral health quality measures, and analyzing policy to guide decision making. For more than two decades, we’ve conducted national surveys of every known mental health and substance use disorder treatment facility in the country.

Our analyses of T-MSIS data for the Centers for Medicare &. Medicaid Services provide critical information on patterns of substance use disorders and treatment across states as evidenced by the T-MSIS Substance Use Disorder (SUD) Data Book and a series of supporting data quality briefs..

As part of our ongoing commitment to prioritizing healing and humanity as we stand against social injustice, Mathematica is walmart viagra price 2020 pleased to announce that President and CEO Paul Decker is joining more than 1,300 CEOs and business leaders as a member of CEO Action for Diversity and Inclusion™. This coalition represents the largest CEO-driven business commitment to advancing workplace diversity, equity, and inclusion, while working to ensure opportunity at the highest levels of corporate leadership.“During a time when the nation continues to be tested by unresolved issues of social justice, Mathematica has taken significant strides toward centering diversity, equity, and inclusion in our interactions with each other and in our approach to our work,” said Decker. €œToday, we’re walmart viagra price 2020 taking another important step forward by joining CEO Action for Diversity and Inclusion, an organization that unites business leaders from around the world to advance DEI initiatives in our own workplaces and beyond.

I’m honored to represent Mathematica in this coalition fighting for meaningful change.”CEO Action represents approximately 13 million employees across more than 85 industries. As a member through its CEO, Mathematica has committed to dedicating time and resources to advancing diversity, equity, and inclusion both within Mathematica and as part of the CEO Action network. Decker has also taken the CEO Action pledge to “check my bias, speak up for walmart viagra price 2020 others and show up for all.”A 100% employee-owned company, Mathematica works with private- and public-sector agencies, corporations, and foundations around the world, using data and evidence to improve the lives of people and communities.

About CEO Action for Diversity &. Inclusion™ CEO Action for Diversity &. Inclusion™ is the largest CEO-driven walmart viagra price 2020 business commitment to advance diversity and inclusion within the workplace.

Bringing together more than 1,000 CEOs of America’s leading organizations, the commitment outlines actions that participating companies pledge to take to cultivate a workplace where diverse perspectives and experiences are welcomed and respected, employees feel comfortable and encouraged to discuss diversity and inclusion, and where best known—and successful—actions can be shared across organizations. Learn more at CEOAction.com and connect with them on Twitter. @CEOAction.

For more information, please contact:Jennifer de Vallancejdevallance@mathematica-mpr.com202-484-4692Mathematica is committed to advancing public health by applying our expertise across disciplines that constitute some of the most critical areas of public health today. The following focus areas highlight how we’re working to progress together to improve public well-being.APHA Public Health Film Festival. Helping Families Affected by Substance UseThe APHA selected a short film that Mathematica produced with support from the Administration for Children and Families to show at the APHA Public Health Film Festival.

The film focuses on how the Regional Partnership Grant program improves the safety, permanency, and well-being of children affected by parent’s substance use disorders. Starting October 19, registered APHA Annual Meeting attendees can watch the film on demand. Registered attendees can also submit questions to Debra Strong a senior researcher for the Regional Partnership Grant National Cross-Site Evaluation, using a discussion board that will be available with the film.

Please visit APHA’s page about public health films focusing on substance use and addiction treatment for more information. Diversity, Equity, and InclusionWhat does it take for organizations to progress together?. It takes a common purpose, shared values, a complementary array of resources and capabilities, and a mutual desire to learn from and with each other.

Our ongoing diversity, equity, and inclusion journey is driving necessary changes in who we are. How we relate to each other, our partners, and our communities. And how we approach our work.

Social Determinants of HealthPolicymakers and practitioners are increasingly interested in social determinants of health—the conditions in which people are born, grow, live, work, and age—to address upstream social risks, such as food insecurity and lack of affordable housing, that, in turn, improve health care outcomes. Mathematica data and policy experts recently produced a series of blog posts and research on how different stakeholders can improve and leverage data on social determinants of health to maximize the health and well-being of children and adults in the United States.erectile dysfunction treatment ServicesResponding to the current public health crisis and illuminating the path forward to safely re-open businesses, schools, workplaces, and community services requires a seasoned partner with trusted solutions. Built on our foundation of rigorous data and evidence, Mathematica’s scalable services provide state and local agencies, as well as private-sector employers, with the confidence and clarity they need to take on the complex challenges of erectile dysfunction treatment.

Some of our services include contact tracing, workforce planning, modeling and forecasting, and wastewater testing and analysis.Data Analytics and Survey ExpertiseAt Mathematica, we apply our expertise at the intersection of data science and social science to produce efficient, high quality, and action-oriented analysis that advances your mission.Using advanced technologies, reusable and scalable platforms, and high-performance secure cloud infrastructure, we enable our partners to target areas of opportunity and make the most of their data. We collect the data you need, manage data as a secure asset, analyze to surface insights, and place this knowledge in the hands of those who need it most.Mental Health and Substance UseMathematica understands the pressing challenges faced by our partners working to improve the delivery system, innovative value-based service models, and financing strategies that states and payers are testing—strategies that could improve the prevention and treatment of behavioral health conditions. We’re leading efforts to address the opioid crisis, increase access to care while controlling costs, and support the integration of behavioral health services with other health care and social services.Our staff have in-depth knowledge of the complex array of intersecting public and private programs and eligibility requirements that create challenges for consumers to get the help they need.

Our work involves evaluating a wide range of behavioral health service delivery and payment models, helping partners establish programs that implement new services and policies and fill data gaps, fielding large-scale behavioral health surveys, developing and implementing behavioral health quality measures, and analyzing policy to guide decision making. For more than two decades, we’ve conducted national surveys of every known mental health and substance use disorder treatment facility in the country. Our analyses of T-MSIS data for the Centers for Medicare &.

Medicaid Services provide critical information on patterns of substance use disorders and treatment across states as evidenced by the T-MSIS Substance Use Disorder (SUD) Data Book and a series of supporting data quality briefs..

Natural viagra

Latest erectile dysfunction News THURSDAY, May 20, 2021 (HealthDay News) A natural viagra small but significant percentage of http://sjaynephotography.com/families/ Americans take medications that can hamper their immune system and its response to erectile dysfunction treatments, researchers say. Their analysis of data from more than 3 million adults under 65 with private insurance found that nearly 3% take immunosuppressive drugs. Those include chemotherapy medications and natural viagra steroids such as prednisone. Two-thirds took an oral steroid at least once, and more than 40% took steroids for more than 30 days in a year, according to findings published May 20 in the journal JAMA Network Open.

Growing evidence suggests that immunosuppressive drugs may reduce effectiveness of erectile dysfunction treatments, increasing patients' risk of severe illness and hospitalization if they get infected. "This study gives us previously unavailable information about how many Americans natural viagra are taking immunosuppressive medications," said lead author Dr. Beth Wallace, a rheumatologist at Michigan Medicine-University of Michigan in Ann Arbor. It also shows that many Americans continue to take oral steroids, which have serious side effects, she said.

Other medicines can often natural viagra be substituted, she added. The new study comes at a time when doctors are beginning to realize that people on immunosuppressants may have a slower, weaker response to erectile dysfunction treatment vaccination, and, in some cases, no response at all. "We don't have a full picture on how these drugs affect the treatment's effectiveness, so it's difficult to formulate guidelines around vaccinating these patients," Wallace said. Researchers are investigating several strategies, including temporarily halting use of immunosuppressive medications around the time of erectile dysfunction treatment vaccination and giving an extra "booster" shot natural viagra.

It's also unclear what people taking immunosuppressive medications should do to protect themselves now that the U.S. Centers for Disease Control and Prevention has relaxed masking and distancing guidelines for vaccinated people. "The CDC acknowledges this cohort natural viagra might not be as protected as other fully vaccinated people, but there are no set recommendations for what precautions they should take," Wallace said. "For now, this is going to be an individual decision people make with their doctor." More research is needed to assess erectile dysfunction treatment response in these patients.

"Until we know more about this, natural viagra we really won't be able to say if immunosuppressed people are actually protected," Wallace said. More information The U.S. Centers for Disease Control and Prevention has more on erectile dysfunction treatments. SOURCE.

Michigan Medicine-University of Michigan, news release, May 20, 2021 Robert Preidt Copyright © 2021 HealthDay. All rights reserved.Latest Neurology News By Amy Norton HealthDay ReporterTHURSDAY, May 20, 2021 (HealthDay News) If you've ever wished you had an extra hand to accomplish a task, never fear, scientists are working on that. But a new study raises questions about how such technology could affect your brain. The findings come from ongoing research into a 3D-printed robotic thumb known as "Third Thumb." It's worn on a person's dominant hand, making it capable of feats that normally demand both hands.

British researchers found that volunteers learned how to use the extra digit quickly -- lifting, carrying, sorting and stacking multiple objects with their single enhanced hand. But there was a possible red flag. MRI scans showed that after just a few days, participants' brains had reorganized the natural hand's "representation" in a movement-related region. It had, in basic terms, shrunk.

It's not clear yet whether that change is good or bad, temporary or not, according to the researchers, from University College London (UCL). But they said it should give the burgeoning field of "motor augmentation" something to consider going forward. Motor augmentation refers to robotic devices that can act as extra fingers or even a whole arm, with the aim of expanding the normal human movement capacity. Here's how the technology works.

Credit. Dani Clode Design and The Plasticity Lab, UCL It might sound like science fiction. But extra digits could come in handy in a range of jobs, according to researcher Dani Clode, the designer of the Third Thumb. As an example, she cited factory workers or engineers who routinely perform repetitive but physically demand tasks.

"An extra pair of hands or digits could assist them in difficult assembly situations, allowing them to do their job in a more safe and efficient way, and perhaps without assistance from others," Clode said. Tamar Makin, a professor of cognitive neuroscience at UCL, said robotic appendages could be used in everything from high-precision scenarios -- like surgery -- to mundane chores. "There are so many things we could do if we had hand extension," Makin said. "We could chop vegetables while stirring a broth, or sip our coffee while typing.

The opportunities are endless, but because this is such a novel concept -- and because our world has been designed to accommodate our five-fingered two hands -- people might struggle to imagine what it could be used for." While many possibilities can be imagined, the researchers also had a caution. No one knows, exactly, how the brain will respond to these robotic add-ons. And these latest findings, published May 19 in the journal Science Robotics, raise questions. Makin, Clode and their colleagues had 36 able-bodied volunteers learn to use the Third Thumb, performing tasks in the lab and "in the wild" of real life.

The device is worn on the pinkie side of the hand, attached by straps that wrap around the wrist and palm. The wearer operates it by manipulating sensors strapped under each big toe. Despite that complicated-sounding toe-robot coordination, the study participants became adept at using the thumb over just five days, the researchers said. But MRI scans of the volunteers' brains revealed a consequence.

The natural hand's representation in the brain had "shrunk." The big unknown is, what does that mean?. Since the extra thumb forced people to alter the way they moved their hand, Makin said, some change in the brain is expected. "What surprised us is how quickly this happened," she said. "After five days of practice to use the thumb, their own hand representation -- which they've been developing over the course of their entire life -- has changed." The researchers found no clear evidence participants lost any ability to use their natural fingers.

But that is something they will monitor going forward. Dr. Eran Klein is a neurologist and affiliate assistant professor at the University of Washington, who studies the intersection of neurology and philosophy. He said he was unsure how much weight to give the new study's findings.

"The brain changes all the time in response to learning skills," Klein noted. Still, he believes the study raises interesting questions. Broadly, Klein said, there's the matter of "what is lost" when humans outsource skills to devices. When we rely on GPS, for instance, what is the consequence for our own navigation prowess?.

With robotic appendages, Klein said, one issue is whether they're inherently different from any other tool people use -- like a screwdriver. QUESTION The abbreviated term ADHD denotes the condition commonly known as. See Answer Probably, he noted, since the devices are worn on the body and resemble human digits or limbs. So what happens when the brain integrates them into the body "schema" -- the felt sense of the body?.

That's not a wholly new concept. People who use a cane, for instance, can start how to get viagra or cialis to feel it's part of them, Klein pointed out. "I think what's interesting about this study," he said, "is that it brings up the bigger question of, what are we going to allow as things that become 'part of us'?. " More Information BrainFacts.org has more on technology and the brain.

SOURCES. Danielle Clode, collaborator, Institute of Cognitive Neuroscience, University College London (UCL). Tamar Makin, PhD, professor, cognitive neuroscience, UCL. Eran Klein, MD, PhD, affiliate assistant professor, department of philosophy, University of Washington, Seattle.

Science Robotics, May 19, 2021, online Copyright © 2021 HealthDay. All rights reserved. From Brain and Nervous System Resources Featured Centers Health Solutions From Our SponsorsLatest erectile dysfunction News By Ernie Mundell and Robin Foster HealthDay ReportersFRIDAY, May 21, 2021 (HealthDay News) treatments approved for use in the United States and Europe show protection against all of the more infectious erectile dysfunction variants known to be circling the globe, the World Health Organization said Thursday. "All erectile dysfunction treatment viagra variants can be controlled in the same way, with public health and social measures," European Regional Director Hans Kluge said during a media briefing, CBS News reported.

"All erectile dysfunction treatment viagra variants that have emerged so far do respond to the available approved treatments." Since January, four variants of concern, including the one bringing India to its knees at the moment, have been monitored by health officials around the world, Kluge said. Known as B.1.617, the Indian variant has been detected in 44 different countries, according to a recent weekly epidemiological update from the WHO, CBS News reported. "For the time being, we can say that all the four variants do respond to the treatments made available, as of today," Kluge said. "But the best way to counteract is to speed up the vaccination rollout." Unknown variants of the viagra could still emerge and be resistant to existing treatments, scientists at Johns Hopkins Medicine said.

And experts noted that variant B.1.351, which first emerged in South Africa, might be resistant to some treatments in development and that mutations like it are still being studied, CBS News reported. Luckily, early trial results have shown that the Moderna treatment provides increased immunity against variants of the viagra found in South Africa and Brazil. And Pfizer's original treatment has been shown to work against the variant first spotted in the United Kingdom, CBS News reported. Should existing treatments fail to protect against any emerging variants in the future, the WHO stated that "it will be possible to change the composition of the treatments to protect against these variants." In the meantime, the news that the treatments are still working comes as countries around the world start to ease some of the social distancing measures that have been in place for over a year.

Throughout America, states have lifted or eased mask mandates following new guidance from the U.S. Centers for Disease Control and Prevention that says fully vaccinated people no longer have to wear them in many instances. But Kluge noted that "there is no such thing as zero risk" and warned people to remain cautious. "treatments may be a light at the end of the tunnel but you cannot be blinded by that light," Kluge said.

"We have been here before. Let us not make the same mistakes that were made this time last year that resulted in the resurgence of erectile dysfunction treatment." He warned people to "exercise caution and rethink or avoid international travel," despite countries around the world reopening to tourism. He also advised adhering to social distancing protocols, wearing a face mask in public, and avoiding crowded spaces. Booster shot likely needed for vaccinated.

Fauci Fully vaccinated people will likely need a erectile dysfunction treatment booster shot within about a year, the nation's top infectious diseases expert and Pfizer's CEO said this week. "We know that the treatment durability of the efficacy lasts at least six months, and likely considerably more, but I think we will almost certainly require a booster sometime within a year or so after getting the primary," Dr. Anthony Fauci told CNN. Fauci also said Wednesday that variant-specific booster shots may not be needed.

"Instead of having to play whack-a-mole with each individual variant and develop a booster that's variant-specific, it is likely that you could just keep boosting against the wild type, and wind up getting a good enough response that you wouldn't have to worry about the variants," he said. The wild type is the original strain of the viagra. Meanwhile, trials of a Pfizer booster treatment are ongoing, company CEO Albert Bourla said. "I believe in one, two months we will have enough data to speak about it with much higher scientific certainty," he told CNN.

"If they got their second shot eight months ago, they may need a third one," Bourla said, adding that booster shots could be coming between September and October of this year. He said Pfizer will have to see what the U.S. Food and Drug Administration approves, and what its recommendation will be on how best to protect the American people. Moderna has also been working on a booster shot -- a half dose of its treatment -- to fight erectile dysfunction treatment variants like B.1.351, first seen in South Africa, and P.1, first discovered in Brazil, CNN reported.

Medical experts believe erectile dysfunction may end up being like the flu, which requires a new shot every year both because the circulating strains mutate quickly and because immunity wears off quickly. Fully vaccinated welcomed to travel to EU countries The fully vaccinated will soon be welcome to visit countries in the European Union, officials there announced this week. The new measures for tourists and other travelers could take effect as early as next week, The New York Times reported. Visitors will be allowed into the bloc's 27 member states if they've been fully immunized with treatments approved by the European Union's regulator or the World Health Organization.

They include the Pfizer, Moderna, Johnson &. Johnson, AstraZeneca and Sinopharm treatments. That would make Americans, who have been receiving shots from Pfizer, Moderna and Johnson &. Johnson, eligible to travel to the EU.

Visitors from countries considered safe from a erectile dysfunction treatment perspective will also be allowed to visit Europe, and a list of those countries will be finalized on Friday, the Times reported. EU member states will still be able to require negative PCR tests or quarantines for certain visitors. The EU will also have a legal "emergency brake" that will let it quickly return to more restrictive travel rules if a threatening new variant or other erectile dysfunction treatment emergency emerges, the Times reported. In the United States, the vaccination picture is improving by the day.

Biden has said there will be enough treatment supply for every American adult by the end of this month. As of Friday, 126.6 million Americans were fully vaccinated and over 57 percent of adults had received at least one dose, according to the CDC. The U.S. Food and Drug Administration also recently approved the Pfizer treatment for adolescents ages 12 to 15.

As of Friday, the U.S. erectile dysfunction case count passed 33 million, while the death toll passed 588,500, according to a tally from Johns Hopkins University. Worldwide, nearly 165.6 million cases had been reported by Wednesday, with nearly 3.4 million people dead from erectile dysfunction treatment. More information The U.S.

Centers for Disease Control and Prevention has more on the new erectile dysfunction. SOURCES. CBS News. CNN.

The New York Times Copyright © 2021 HealthDay. All rights reserved..

Latest erectile dysfunction News THURSDAY, May 20, 2021 (HealthDay News) A walmart viagra price 2020 small but significant percentage of viagra price Americans take medications that can hamper their immune system and its response to erectile dysfunction treatments, researchers say. Their analysis of data from more than 3 million adults under 65 with private insurance found that nearly 3% take immunosuppressive drugs. Those include chemotherapy medications and steroids such as prednisone walmart viagra price 2020.

Two-thirds took an oral steroid at least once, and more than 40% took steroids for more than 30 days in a year, according to findings published May 20 in the journal JAMA Network Open. Growing evidence suggests that immunosuppressive drugs may reduce effectiveness of erectile dysfunction treatments, increasing patients' risk of severe illness and hospitalization if they get infected. "This study gives us previously unavailable information about walmart viagra price 2020 how many Americans are taking immunosuppressive medications," said lead author Dr.

Beth Wallace, a rheumatologist at Michigan Medicine-University of Michigan in Ann Arbor. It also shows that many Americans continue to take oral steroids, which have serious side effects, she said. Other medicines can often be walmart viagra price 2020 substituted, she added.

The new study comes at a time when doctors are beginning to realize that people on immunosuppressants may have a slower, weaker response to erectile dysfunction treatment vaccination, and, in some cases, no response at all. "We don't have a full picture on how these drugs affect the treatment's effectiveness, so it's difficult to formulate guidelines around vaccinating these patients," Wallace said. Researchers are investigating several strategies, including temporarily halting use of walmart viagra price 2020 immunosuppressive medications around the time of erectile dysfunction treatment vaccination and giving an extra "booster" shot.

It's also unclear what people taking immunosuppressive medications should do to protect themselves now that the U.S. Centers for Disease Control and Prevention has relaxed masking and distancing guidelines for vaccinated people. "The CDC acknowledges this cohort might not be as protected as other fully vaccinated people, walmart viagra price 2020 but there are no set recommendations for what precautions they should take," Wallace said.

"For now, this is going to be an individual decision people make with their doctor." More research is needed to assess erectile dysfunction treatment response in these patients. "Until we know more about this, we really won't be able to say if walmart viagra price 2020 immunosuppressed people are actually protected," Wallace said. More information The U.S.

Centers for Disease Control and Prevention has more on erectile dysfunction treatments. SOURCE. Michigan Medicine-University of Michigan, news release, May 20, 2021 Robert Preidt Copyright © 2021 HealthDay.

All rights reserved.Latest Neurology News By Amy Norton HealthDay ReporterTHURSDAY, May 20, 2021 (HealthDay News) If you've ever wished you had an extra hand to accomplish a task, never fear, scientists are working on that. But a new study raises questions about how such technology could affect your brain. The findings come from ongoing research into a 3D-printed robotic thumb known as "Third Thumb." It's worn on a person's dominant hand, making it capable of feats that normally demand both hands.

British researchers found that volunteers learned how to use the extra digit quickly -- lifting, carrying, sorting and stacking multiple objects with their single enhanced hand. But there was a possible red flag. MRI scans showed that after just a few days, participants' brains had reorganized the natural hand's "representation" in a movement-related region.

It had, in basic terms, shrunk. It's not clear yet whether that change is good or bad, temporary or not, according to the researchers, from University College London (UCL). But they said it should give the burgeoning field of "motor augmentation" something to consider going forward.

Motor augmentation refers to robotic devices that can act as extra fingers or even a whole arm, with the aim of expanding the normal human movement capacity. Here's how the technology works. Credit.

Dani Clode Design and The Plasticity Lab, UCL It might sound like science fiction. But extra digits could come in handy in a range of jobs, according to researcher Dani Clode, the designer of the Third Thumb. As an example, she cited factory workers or engineers who routinely perform repetitive but physically demand tasks.

"An extra pair of hands or digits could assist them in difficult assembly situations, allowing them to do their job in a more safe and efficient way, and perhaps without assistance from others," Clode said. Tamar Makin, a professor of cognitive neuroscience at UCL, said robotic appendages could be used in everything from high-precision scenarios -- like surgery -- to mundane chores. "There are so many things we could do if we had hand extension," Makin said.

"We could chop vegetables while stirring a broth, or sip our coffee while typing. The opportunities are endless, but because this is such a novel concept -- and because our world has been designed to accommodate our five-fingered two hands -- people might struggle to imagine what it could be used for." While many possibilities can be imagined, the researchers also had a caution. No one knows, exactly, how the brain will respond to these robotic add-ons.

And these latest findings, published May 19 in the journal Science Robotics, raise questions. Makin, Clode and their colleagues had 36 able-bodied volunteers learn to use the Third Thumb, performing tasks in the lab and "in the wild" of real life. The device is worn on the pinkie side of the hand, attached by straps that wrap around the wrist and palm.

The wearer operates it by manipulating sensors strapped under each big toe. Despite that complicated-sounding toe-robot coordination, the study participants became adept at using the thumb over just five days, the researchers said. But MRI scans of the volunteers' brains revealed a consequence.

The natural hand's representation in the brain had "shrunk." The big unknown is, what does that mean?. Since the extra thumb forced people to alter the way they moved their hand, Makin said, some change in the brain is expected. "What surprised us is how quickly this happened," she said.

"After five days of practice to use the thumb, their own hand representation -- which they've been developing over the course of their entire life -- has changed." The researchers found no clear evidence participants lost any ability to use their natural fingers. But that is something they will monitor going forward. Dr.

Eran Klein is a neurologist and affiliate assistant professor at the University of Washington, who studies the intersection of neurology and philosophy. He said he was unsure how much weight to give the new study's findings. "The brain changes all the time in response to learning skills," Klein noted.

Still, he believes the study raises interesting questions. Broadly, Klein said, there's the matter of "what is lost" when humans outsource skills to devices. When we rely on GPS, for instance, what is the consequence for our own navigation prowess?.

With robotic appendages, Klein said, one issue is whether they're inherently different from any other tool people use -- like a screwdriver. QUESTION The abbreviated term ADHD denotes the condition commonly known as. See Answer Probably, he noted, since the devices are worn on the body and resemble human digits or limbs.

So what happens when the brain integrates them into the body "schema" -- the felt sense of the body?. That's not a wholly new concept. People who use a cane, for instance, can start to feel it's part of them, Klein pointed out.

"I think what's interesting about this study," he said, "is that it brings up the bigger question of, what are we going to allow as things that become 'part of us'?. " More Information BrainFacts.org has more on technology and the brain. SOURCES.

Danielle Clode, collaborator, Institute of Cognitive Neuroscience, University College London (UCL). Tamar Makin, PhD, professor, cognitive neuroscience, UCL. Eran Klein, MD, PhD, affiliate assistant professor, department of philosophy, University of Washington, Seattle.

Science Robotics, May 19, 2021, online Copyright © 2021 HealthDay. All rights reserved. From Brain and Nervous System Resources Featured Centers Health Solutions From Our SponsorsLatest erectile dysfunction News By Ernie Mundell and Robin Foster HealthDay ReportersFRIDAY, May 21, 2021 (HealthDay News) treatments approved for use in the United States and Europe show protection against all of the more infectious erectile dysfunction variants known to be circling the globe, the World Health Organization said Thursday.

"All erectile dysfunction treatment viagra variants can be controlled in the same way, with public health and social measures," European Regional Director Hans Kluge said during a media briefing, CBS News reported. "All erectile dysfunction treatment viagra variants that have emerged so far do respond to the available approved treatments." Since January, four variants of concern, including the one bringing India to its knees at the moment, have been monitored by health officials around the world, Kluge said. Known as B.1.617, the Indian variant has been detected in 44 different countries, according to a recent weekly epidemiological update from the WHO, CBS News reported.

"For the time being, we can say that all the four variants do respond to the treatments made available, as of today," Kluge said. "But the best way to counteract is to speed up the vaccination rollout." Unknown variants of the viagra could still emerge and be resistant to existing treatments, scientists at Johns Hopkins Medicine said. And experts noted that variant B.1.351, which first emerged in South Africa, might be resistant to some treatments in development and that mutations like it are still being studied, CBS News reported.

Luckily, early trial results have shown that the Moderna treatment provides increased immunity against variants of the viagra found in South Africa and Brazil. And Pfizer's original treatment has been shown to work against the variant first spotted in the United Kingdom, CBS News reported. Should existing treatments fail to protect against any emerging variants in the future, the WHO stated that "it will be possible to change the composition of the treatments to protect against these variants." In the meantime, the news that the treatments are still working comes as countries around the world start to ease some of the social distancing measures that have been in place for over a year.

Throughout America, states have lifted or eased mask mandates following new guidance from the U.S. Centers for Disease Control and Prevention that says fully vaccinated people no longer have to wear them in many instances. But Kluge noted that "there is no such thing as zero risk" and warned people to remain cautious.

"treatments may be a light at the end of the tunnel but you cannot be blinded by that light," Kluge said. "We have been here before. Let us not make the same mistakes that were made this time last year that resulted in the resurgence of erectile dysfunction treatment." He warned people to "exercise caution and rethink or avoid international travel," despite countries around the world reopening to tourism.

He also advised adhering to social distancing protocols, wearing a face mask in public, and avoiding crowded spaces. Booster shot likely needed for vaccinated. Fauci Fully vaccinated people will likely need a erectile dysfunction treatment booster shot within about a year, the nation's top infectious diseases expert and Pfizer's CEO said this week.

"We know that the treatment durability of the efficacy lasts at least six months, and likely considerably more, but I think we will almost certainly require a booster sometime within a year or so after getting the primary," Dr. Anthony Fauci told CNN. Fauci also said Wednesday that variant-specific booster shots may not be needed.

"Instead of having to play whack-a-mole with each individual variant and develop a booster that's variant-specific, it is likely that you could just keep boosting against the wild type, and wind up getting a good enough response that you wouldn't have to worry about the variants," he said. The wild type is the original strain of the viagra. Meanwhile, trials of a Pfizer booster treatment are ongoing, company CEO Albert Bourla said.

"I believe in one, two months we will have enough data to speak about it with much higher scientific certainty," he told CNN. "If they got their second shot eight months ago, they may need a third one," Bourla said, adding that booster shots could be coming between September and October of this year. He said Pfizer will have to see what the U.S.

Food and Drug Administration approves, and what its recommendation will be on how best to protect the American people. Moderna has also been working on a booster shot -- a half dose of its treatment -- to fight erectile dysfunction treatment variants like B.1.351, first seen in South Africa, and P.1, first discovered in Brazil, CNN reported. Medical experts believe erectile dysfunction may end up being like the flu, which requires a new shot every year both because the circulating strains mutate quickly and because immunity wears off quickly.

Fully vaccinated welcomed to travel to EU countries The fully vaccinated will soon be welcome to visit countries in the European Union, officials there announced this week. The new measures for tourists and other travelers could take effect as early as next week, The New York Times reported. Visitors will be allowed into the bloc's 27 member states if they've been fully immunized with treatments approved by the European Union's regulator or the World Health Organization.

They include the Pfizer, Moderna, Johnson &. Johnson, AstraZeneca and Sinopharm treatments. That would make Americans, who have been receiving shots from Pfizer, Moderna and Johnson &.

Johnson, eligible to travel to the EU. Visitors from countries considered safe from a erectile dysfunction treatment perspective will also be allowed to visit Europe, and a list of those countries will be finalized on Friday, the Times reported. EU member states will still be able to require negative PCR tests or quarantines for certain visitors.

The EU will also have a legal "emergency brake" that will let it quickly return to more restrictive travel rules if a threatening new variant or other erectile dysfunction treatment emergency emerges, the Times reported. In the United States, the vaccination picture is improving by the day. Biden has said there will be enough treatment supply for every American adult by the end of this month.

As of Friday, 126.6 million Americans were fully vaccinated and over 57 percent of adults had received at least one dose, according to the CDC. The U.S. Food and Drug Administration also recently approved the Pfizer treatment for adolescents ages 12 to 15.

As of Friday, the U.S. erectile dysfunction case count passed 33 million, while the death toll passed 588,500, according to a tally from Johns Hopkins University. Worldwide, nearly 165.6 million cases had been reported by Wednesday, with nearly 3.4 million people dead from erectile dysfunction treatment.

More information The U.S. Centers for Disease Control and Prevention has more on the new erectile dysfunction. SOURCES.

CBS News. CNN. The New York Times Copyright © 2021 HealthDay.

How many mg of viagra should i take

Listen and subscribe on Apple, Stitcher, Spotify, and click reference Google, so you don't how many mg of viagra should i take miss the next episode. And if you like what you hear, a five-star rating goes a long way in helping us "Track the Vax"!. Vaccination across the nation is now underway, with healthcare workers and those living and working in long-term care facilities among the first to receive the treatments. Long-term and nursing how many mg of viagra should i take home residents make up about 1% of the U.S.

Population, but have accounted for roughly 40% of all erectile dysfunction treatment deaths, while those older than 50 are more likely to die from erectile dysfunction treatment than younger age groups. However, they've accounted for less than a quarter of total erectile dysfunction treatment clinical trial participants. Why are they how many mg of viagra should i take so scarcely represented in trials?. To learn more, we chatted with Sharon Inouye, MD, MPH, a professor of medicine at Harvard Medical School and geriatrician at Hebrew Senior Life.

She is also director of the Aging Brain Center at the Hinda and Arthur Marcus Institute for Aging Research. The episode kicks off with a how many mg of viagra should i take discussion with 60-year old clinical trial participant Kelley Pick, to hear about her experience in a trial.The following is a transcript of their interviews with "Track the Vax" host Serena Marshall:Serena Marshall. Kelley, thanks for joining us here at "Track the Vax." Tell me what made you want to sign up for a clinical trial.Kelley Pick. To be honest, since erectile dysfunction treatment started, I would say I'd stand on my head to make this go away and...

Late summer, I was watching TV with my granddaughter and a commercial came in, came on for our local station and said that Meridian was looking for participants age 55 and older how many mg of viagra should i take to join the Pfizer treatment study.And my granddaughter said, "grandma, you should do that." And I thought, yes I should.Marshall. So she really was your impetus to go ahead and sign up. What did you think when you were signing up for this?. Pick.

You know, a little hesitant, we thought, well, let's check it out because we do have to do something to make this go away. And it was just a 40 minute drive and did it online. Registered online and they called back and answered all our questions. My husband said, well, I'll do it with you.

So the both of us did.Marshall. Why don't you walk us through that process?. Pick. We registered online, found the website, which was mentioned on the television commercial, and then we got a phone call back.

Telling us that this was with Meridians Pfizer's treatment study, and they asked us some questions and we both qualified for the 55 and older study. So that was back in August.And they said that we qualified and they'd be calling us to set up a time.We got the phone call to come on down. And the first thing they did was to test us, to see if we currently had the viagra or if we had antibodies showing that we've already had it.And they did not want those type of participants. They were looking for clean people, I guess.

So they can find out if the treatment worked and we both did pass that test.Marshall. Now, getting that treatment though, I'm sure it must have been a little anxiety inducing. It's a clinical trial. You're not really sure what to expect.

How did they prepare you for that?. Pick. They did. And talking to some other professionals, we were in phase three of the study.

Where, I think phase two is where they work on if there was any health hazards, more side effects. So we felt pretty confident being part of the phase three study that if they're worth something's in there, they had worked out.So we were pretty confident going into it. We teased each other about growing a third eye, but... [laughter]Marshall.

Do you think that you and your husband received the same one?. Whether it be the treatment or the placebo?. Pick. You know, I would have to say, I doubt it just because they have a perfect 50/50 case study and I read up on it and I know where they feel so confident in the treatment is that one spouse that was part of the study may get the viagra and the other spouse does not.

So we both hope we have the treatment, but we don't know.Marshall. If they unblinded it and found out that you or your husband was a placebo recipient, would you then still go forward and get the full treatment or would you wait it out?. So you could be that control group.Pick. We would probably get the treatment because to be honest, that's why we signed up for the study.

That we want it to move on with our lives and we feel the treatment is so good. Um, we will listen to them and find out how important that is, you know, for the case study to continue. So. I can't say that I'm a hundred percent sure that if I received the placebo, that I would say, no, I want the treatment.Like I said, I would listen to them and find out how many they need.

But if all things are the same and it doesn't really matter, I can't wait to get the treatment.Marshall. And one of the things that they don't know about this treatment is long-term immunity, but also if you can still get erectile dysfunction treatment and be a carrier, pass it on, even though you might not have a bad reaction to it. Is that something that concerns you and your husband?. Pick.

We definitely do not want to be erectile dysfunction treatment spreaders. And so, you know, we still would follow up on the professionals advice and do things like that. But as far as worrying about our own health, the treatment is not near as bad, I believe, as getting the viagra.Marshall. It's a new technology, mRNA treatment.

Did they talk to you about that when you went into it?. Pick. Yes. And they all so said that at any time that we would like to get a different treatment, there would be no problem in dropping out of the study and getting a different treatment.

Right now, to be honest, we got this treatment because of how close the clinic was to us. And I'm sure with modern technology we're going to have a lot of great treatments.So we'll just have to wait and see.Marshall. What do you tell your granddaughter who encouraged you to sign up?. Pick.

I told her I was doing this podcast today and said, if it's alright with you, I'm going to tell them the truth about this. And I do feel it's such a good conversation to have with our young children. She's had to miss a few days of school because she was exposed. And she did not like that being at home.So getting our kids back in school, those types are the really important things to get back to normal.

-- Marshall. Dr. Inouye , thank you so much for joining us here at "Track the Vax."Sharon Inouye, MD. I'm delighted to be here today.

Thank you for inviting me.Marshall. Dr. Inouye, we want to talk about some of the erectile dysfunction treatment trials and the age of those trial participants. Now we've seen in the erectile dysfunction treatment study for Pfizer, those over the age or above 75, we're only 4% of the study, with Moderna above 65.We're only at about 25% of the study.

Is that an acceptable breakdown of the cohort?. When you're looking at who's getting these treatments?. Inouye. Yeah.

So Serena, those are really good questions. I would, of course love to see more robust numbers represented in both those trials. But I think the reality is they did make great efforts to try to include some of the population. And I know the group 65 to 75 included about 2200 patients, which was about 21% of their cohort.But then, as you just said, 75 and older was only 4% of the cohort or about 1,700 patients.

But I think it's noteworthy to state that some of those, Older adults included also had comorbidities like hypertension, diabetes, chronic pulmonary disease.So they really did make efforts to try to get individuals who would be more representative of our older adults. I don't think though that any nursing home patients were included. At least there are, there's no indication that they did. And so the testing in that population, I think has been very limited in both the Pfizer and the Moderna treatmentsMarshall.

Why is it so important to specifically study those in nursing homes, if you're looking at the age cohort that nursing home residents include?. Inouye. The hardest hit venue in terms of proportion of severe illness from erectile dysfunction treatment and death has been in our long-term care facilities in our country. That is a targeted priority group as identified by multiple expert panels and advisory groups, and they are being targeted in phase one of the treatment release effort.I think everyone would agree.

It would have been beneficial if there, if there had been more testing in that population prior to the release.Marshall. When you look at that age group, what we heard a lot about at the different committee meeting hearings on these two different treatments where you could extrapolate the data and have it represent those older Americans pretty well. Is that not really the case or are there different reasons that that older group needed to be a more robust number in these clinical trials?. Inouye.

That's a really good question. Serena. I do think that the population in long-term care facilities tends to have more comorbidities, meaning more chronic diseases. They're on more medications.

A lot of times there's a high prevalence of cognitive and functional decline. And also we know from other types of vaccination studies that the immune response may be less robust than in younger populations are, or even the same age populations that are not in a nursing home.And so yes, to test both the efficacy of the treatment and potential side effects of the treatment in that population would have been helpful, I believe, but I think you can still extrapolate that the treatment will have some effectiveness. I think it's just not clear how robust that will be exactly.And also the, what the exact side effect profile might be.Marshall. As a geriatrician, does it concern you that there's still so much we don't know about that specific cohort these different treatments?.

Inouye. Yes. Well, I wear two different hats and as a geriatrician, yes, it does really concern me, and I think about it all the time and patients are asking me, should I get it?. I'm not sure I feel totally comfortable that it's been adequately tested.

And my response is influenced by several factors.First, is that in any kind of treatment or treatment trial, you have limitations in what you can accomplish, right?. In the clinical trials, there's always that limitations. And even with the flu treatments that we're very used to giving to this population every year. The individual flu treatments each year are not robustly tested in the nursing home population either.And so that's not unusual.

And similarly for other treatments, they're not always tested in older adults before they're released to the market.Marshall. Why is that?. Inouye. I think it's the case because, frankly, there, there is some degree of age-ism in our country, and that population can be more challenging and difficult to study and can delay your procedures.

It can be more expensive and there can be more side effects. And so I think, obviously if you're a drug developer and you're trying to develop something quickly and you want it to have the least side effects, then you are going to shy away from that population.And there's been a lot written about this in terms of cancer drugs, and cardiac drugs, and a lot of other treatments that are primarily the largest audience, the largest target population is older adults that the testing hasn't been adequate in the past. And the National Institutes of Health has even created a new policy that older adults must be included in any trials that are funded by them.Marshall. That's interesting.

That's a new policy?. Inouye. It went into effect at the beginning of 2019, so fairly new.Marshall. Quite shocking.

It's taken us this long to have that as a necessity.Inouye. Exactly, exactly. And so that's still an issue. And I think it's both logistical, but also I think there is an attitude that it's not necessary to include older adults.

And that's what I'm really trying to fight against.Marshall. But how do you drum up interest in getting more older adults to want to participate in clinical trials?. Inouye. So there is huge interest amongst older adults in participating.

And in fact, I had hundreds of people reach out to me after one of my articles came out about "how do I get into a trial or, I volunteered and I was turned down." I can't tell you how many times I heard that. Just an outpouring of interest. And, I think a lot of it depended on how physically close you lived to a clinical trial site and then just the strategy by which they were doing outreach. But I think a lot of older adults were very, very willing to participate.I run studies and trials in the over 70 population and it's just amazing how much that generation wants to contribute to science and to advancing healthcare and to leaving a legacy.

And feel it's very important. They feel it's part of their mission. And I did want to say that I do think that's another reason why older adults would be willing to get the treatment, because I do think many of them feel it's their public duty.Marshall. Is that a different way of thinking one generation to the next?.

Inouye. I think so. I mean, I see it very much in that older generation and I think it's a different mindset, right?. This was the same generation though, that lived through World War 2 and was used to doing things for the country and, do a lot of self sacrifice for the sake of the country.And I kind of feel like that attitude has been lost in our country.Marshall.

You said though that a lot of them were turned away from the clinical trial, but it seemed that they were having trouble enrolling that age group. So what is the juxtaposition there?. Inouye. It's similar to what I wrote up in my paper in JAMA Internal Medicine, that many of the trials had what I consider to be ageist, exclusionary criteria criteria that were unjustifiably, excluding older adults, like requiring that they communicate by text messaging, requiring that they have Wi-Fi at home that they were using regularly, that they would respond to immediate messages on their Wi-Fi.You know, and that just, why can they call them on the phone?.

I'm not sure that's why these particular patients were excluded, but there were also other criteria that didn't seem well justified, like very well controlled, mild comorbidities. Didn't seem like a justifiable exclusionary criteria. Maybe they had trouble with their vision or their hearing and that should be something you could adapt to and should not be an exclusionary criteria, but it was from some of the studies that we found. There's no reason from a medical standpoint, right.

That, that should be an exclusion.Marshall. You would think that nursing home residents might be an easy group to include in a clinical trial because you have somebody there who's essentially monitoring their vitals and their wellbeing on a day-to-day basis.Inouye. Yup. Yup.

I totally agree.Marshall. That's not the case?. Inouye. It's not the case because I think they're viewed as high risk.

You may need to get proxy consent, meaning from a family member. And so it takes extra time. But I think the reality is the concerns that your results may not look quite as good, right, in that population. And so it may slow down your time to approval.Marshall.

So you're saying because they have more comorbidities or have other factors that would play into how they received the treatment, they might not be giving the clinical trial the results they're looking for?. Inouye. Right because their immune response may be a bit less robust. And so they may get more s despite the treatment.

And then there may also be more side effects.Marshall. One would think that you would want to know those things before mass distribution of a product.Inouye. One would think so. I agree, but I think that you can understand if you were on the side of expediency, right.

That it may slow you down. It may make your results look worse and so...Marshall. So we wouldn't be seeing that 95% efficacy.Inouye. We may not.

You can call it age-ism or you can call it expediency. I would have wanted it tested in that population and I would have liked to see the results in that population.But again, that's rarely done with any treatment before it's released.Marshall. What are you seeing as some of the major concerns?. Among older adults ....caregivers for older adults when it comes to getting the treatment?.

Inouye. Well, I'm hearing a lot that. "This has been so rushed. Are we sure it's okay?.

Are we sure it's safe?. Has it been adequately tested?. Do we know that it works?. Do we know it's not going to have side effects?.

"Marshall. Those are a lot of the same questions we're hearing among younger...Inouye. ...everybody, right?. Yes.

I think it's all the same concerns and. And I totally validate where those questions are coming from. We have to admit that this project Warp Speed and all of these treatments have been developed in an amazing process and amazing burst of incredible science, frankly, it's a miracle.But I think the best science has gone into it. The testing has been there.

I think everything has been done according to strict guidelines and standards. As soon as my number is called, I'm going to be in line to get it. And I have a 91 year old mother. We are all firmly united that the risks to my mother of getting erectile dysfunction treatment are so much higher then the risks of side effects that could be serious, but we know are going to be rare.But it's a gamble that where, I think the equation is definitely in favor of getting the treatment.Marshall.

When you look at some of the public prominent figures who we've seen getting the treatment, some of the prominent older celebrities, or even politicians. Does that play a role in helping alleviate some of the concerns specifically among this subgroup who in some cases were alive during the polio treatment. Saw the Elvis push -- does that play a key role in maybe helping them decide to get it or not?. Inouye.

I think it does raise confidence. I think when they see, people they admire and respect and trust getting the treatment...I mean, it reassures me right, when Tony Fauci gets the treatment, then I know like, I'm okay. He's my hero.This is really going to change the equation in our favor in favor of humankind. Once we can get everybody vaccinated.Marshall.

When we look at this treatment, there's two doses. How do you ensure uptake among this group of getting both doses?. They might go in for the first and then the pain and the discomfort, dissuade them from following up with the second.Inouye. Yeah, I think in the long-term care setting, that's easier to control because they're there in the facility.

If it's someone who has to go back. I don't know exactly what healthcare professionals or like if it's through CVS or Walgreens, I'm sure there are reminder systems and follow-ups.I am hoping that people will get the second one because definitely, to go through the first one and not then make sure you have adequate immunity. It's sort of like going through the pain and not getting the gain. And so I hope people will be willing to get both.The side effects, they can be uncomfortable, no question.

The painful arm and the flu-like syndrome for a day or two.But, you know, those are signs that it's working and probably similar to other treatments that people have received.Marshall. I want to come back to that question of age-ism. There was some debate when discussing who should get the treatment and in what order .... Essential workers versus elder Americans more broadly, not talking about those nursing home residents.

Now we know older Americans are more susceptible to erectile dysfunction treatment.We talked about how they have more comorbidities in some cases related to their age, but then there's the question of the essential workers and the need to get the economy back up and running. This is definitely an ethical question, but is it one that ultimately... Does it come down to the question of age-ism?. Inouye.

Yeah. It's a really good question. I campaigned very hard for older adults to be included in that phase one. And older adults with comorbidities are included in that phase one.

So that is the highest risk population in older adults as well in the facilities.I think in part, it may have been influenced by age-ism, but also in part just by practicality. Right?. You know, you're only going to have a limited amount of treatment early on, and it is, I do agree. It's really important to have frontline healthcare workers, for instance, protected because they can also spread it, right?.

Amongst many others, other patients who were very ill and then also that the staff in facilities, as well. In fact, I don't know the exact percentage, but it's been well-documented that many of the outbreaks in long-term care facilities are initiated or propagated by staff. And so I think that's really important that staff in long-term care facilities be in that first group, which they are.And so I think that will help both with spread and curtailing the . I mean, ideally what we're hoping is everyone, right.

Will be able to be vaccinated within a few months, ideally by the late spring. Definitely by the fall, it's projected that there will be enough for everyone who wants to get vaccinated to be vaccinated.Marshall. So, looking at this specific age cohort....Where do we go from here?. What have these treatment trials for erectile dysfunction treatment taught us when it comes to elder inclusion in clinical trials more broadly?.

Inouye. I honestly thought a better job would be done. That's really what I had hoped for because of knowing that, the population so affected with erectile dysfunction treatment was so disproportionately skewed to older adults. I thought this has gotta be the point at which this will change.

This, this has gotta change it.And in reality, I mean, some efforts were made, right. The age range in the Pfizer trial was 75 to 91. So there were efforts made to include people, in their eighties and even someone 91. So that's incredible.

But, as we pointed out at the beginning, it was less than 4% right. Of the overall trial population.So, that was disappointing. Very small icing on the cake. It just wasn't a genuine effort.Marshall.

So, did we learn anything as a society then?. Inouye. I don't know....I haven't heard a loud public outcry about it, which was disappointing. I had hoped that would happen.

I think, when I talk to people working at the FDA about this, they also acknowledge this. They also predicted that there wouldn't be very many included and that the argument was going to be well, this will all be testing, tested in post-marketing surveys, which is how most of the product testing happens in older adults.After approval in what's called post-marketing surveillance. And, I had hoped this would be different in that, because of the demographics of erectile dysfunction treatment that we could make it different. And so I'm hoping to continue to use this as an example, and as a platform for maybe changing things in the future.I think people are stepping up and speaking out for our older population, but it's going to take a while to make these major changes happen, right?.

And there's going to need to be policy change and regulation change. And I was so disappointed when the FDA did not require older adults, a certain proportion to be enrolled.That's what I was so hoping would happen. And they did not require it. It was a recommendation, but no stronger than that.

And that's where we need to change things. It needs to happen at a policy level. And so I'm hoping over the course of time and with what we've seen here, what we've learned, what we've shown, that we can start to make those changes happen at the policy level.Marshall. I hope that you'll keep us updated on how those policy changes go as you continue to push forward on this issue.

Thank you so much for joining us here at "Track the Vax." One of the last questions we love to ask everyone. I know you mentioned it earlier, when it's your turn in line, you do plan to get the treatment?. Inouye. I do hope to get the treatment.

The system crashed at my hospital because of too many healthcare professionals wanting to sign up all in the same day. So, I decided to wait a little while longer to sign up.I don't work in the emergency room or in the intensive care units. So, I'll probably be in the... I'll definitely be able to get it, but I don't know exactly when.

But I'm hoping to be able to get it soon.Marshall. Well, good luck. And thank you again for your time.Inouye. Okay.

Listen and subscribe on Apple, Stitcher, Spotify, and Google, so you walmart viagra price 2020 don't miss the Where can i buy amoxil next episode. And if you like what you hear, a five-star rating goes a long way in helping us "Track the Vax"!. Vaccination across the nation is now underway, with healthcare workers and those living and working in long-term care facilities among the first to receive the treatments.

Long-term and nursing home residents make up about 1% of the walmart viagra price 2020 U.S. Population, but have accounted for roughly 40% of all erectile dysfunction treatment deaths, while those older than 50 are more likely to die from erectile dysfunction treatment than younger age groups. However, they've accounted for less than a quarter of total erectile dysfunction treatment clinical trial participants.

Why are walmart viagra price 2020 they so scarcely represented in trials?. To learn more, we chatted with Sharon Inouye, MD, MPH, a professor of medicine at Harvard Medical School and geriatrician at Hebrew Senior Life. She is also director of the Aging Brain Center at the Hinda and Arthur Marcus Institute for Aging Research.

The episode kicks off with a discussion with 60-year old clinical trial participant Kelley Pick, to hear about her experience in a trial.The walmart viagra price 2020 following is a transcript of their interviews with "Track the Vax" host Serena Marshall:Serena Marshall. Kelley, thanks for joining us here at "Track the Vax." Tell me what made you want to sign up for a clinical trial.Kelley Pick. To be honest, since erectile dysfunction treatment started, I would say I'd stand on my head to make this go away and...

Late summer, I was watching TV walmart viagra price 2020 with my granddaughter and a commercial came in, came on for our local station and said that Meridian was looking for participants age 55 and older to join the Pfizer treatment study.And my granddaughter said, "grandma, you should do that." And I thought, yes I should.Marshall. So she really was your impetus to go ahead and sign up. What did you think when you were signing up for this?.

Pick. You know, a little hesitant, we thought, well, let's check it out because we do have to do something to make this go away. And it was just a 40 minute drive and did it online.

Registered online and they called back and answered all our questions. My husband said, well, I'll do it with you. So the both of us did.Marshall.

Why don't you walk us through that process?. Pick. We registered online, found the website, which was mentioned on the television commercial, and then we got a phone call back.

Telling us that this was with Meridians Pfizer's treatment study, and they asked us some questions and we both qualified for the 55 and older study. So that was back in August.And they said that we qualified and they'd be calling us to set up a time.We got the phone call to come on down. And the first thing they did was to test us, to see if we currently had the viagra or if we had antibodies showing that we've already had it.And they did not want those type of participants.

They were looking for clean people, I guess. So they can find out if the treatment worked and we both did pass that test.Marshall. Now, getting that treatment though, I'm sure it must have been a little anxiety inducing.

It's a clinical trial. You're not really sure what to expect. How did they prepare you for that?.

Pick. They did. And talking to some other professionals, we were in phase three of the study.

Where, I think phase two is where they work on if there was any health hazards, more side effects. So we felt pretty confident being part of the phase three study that if they're worth something's in there, they had worked out.So we were pretty confident going into it. We teased each other about growing a third eye, but...

[laughter]Marshall. Do you think that you and your husband received the same one?. Whether it be the treatment or the placebo?.

Pick. You know, I would have to say, I doubt it just because they have a perfect 50/50 case study and I read up on it and I know where they feel so confident in the treatment is that one spouse that was part of the study may get the viagra and the other spouse does not. So we both hope we have the treatment, but we don't know.Marshall.

If they unblinded it and found out that you or your husband was a placebo recipient, would you then still go forward and get the full treatment or would you wait it out?. So you could be that control group.Pick. We would probably get the treatment because to be honest, that's why we signed up for the study.

That we want it to move on with our lives and we feel the treatment is so good. Um, we will listen to them and find out how important that is, you know, for the case study to continue. So.

I can't say that I'm a hundred percent sure that if I received the placebo, that I would say, no, I want the treatment.Like I said, I would listen to them and find out how many they need. But if all things are the same and it doesn't really matter, I can't wait to get the treatment.Marshall. And one of the things that they don't know about this treatment is long-term immunity, but also if you can still get erectile dysfunction treatment and be a carrier, pass it on, even though you might not have a bad reaction to it.

Is that something that concerns you and your husband?. Pick. We definitely do not want to be erectile dysfunction treatment spreaders.

And so, you know, we still would follow up on the professionals advice and do things like that. But as far as worrying about our own health, the treatment is not near as bad, I believe, as getting the viagra.Marshall. It's a new technology, mRNA treatment.

Did they talk to you about that when you went into it?. Pick. Yes.

And they all so said that at any time that we would like to get a different treatment, there would be no problem in dropping out of the study and getting a different treatment. Right now, to be honest, we got this treatment because of how close the clinic was to us. And I'm sure with modern technology we're going to have a lot of great treatments.So we'll just have to wait and see.Marshall.

What do you tell your granddaughter who encouraged you to sign up?. Pick. I told her I was doing this podcast today and said, if it's alright with you, I'm going to tell them the truth about this.

And I do feel it's such a good conversation to have with our young children. She's had to miss a few days of school because she was exposed. And she did not like that being at home.So getting our kids back in school, those types are the really important things to get back to normal.

-- Marshall. Dr. Inouye , thank you so much for joining us here at "Track the Vax."Sharon Inouye, MD.

I'm delighted to be here today. Thank you for inviting me.Marshall. Dr.

Inouye, we want to talk about some of the erectile dysfunction treatment trials and the age of those trial participants. Now we've seen in the erectile dysfunction treatment study for Pfizer, those over the age or above 75, we're only 4% of the study, with Moderna above 65.We're only at about 25% of the study. Is that an acceptable breakdown of the cohort?.

When you're looking at who's getting these treatments?. Inouye. Yeah.

So Serena, those are really good questions. I would, of course love to see more robust numbers represented in both those trials. But I think the reality is they did make great efforts to try to include some of the population.

And I know the group 65 to 75 included about 2200 patients, which was about 21% of their cohort.But then, as you just said, 75 and older was only 4% of the cohort or about 1,700 patients. But I think it's noteworthy to state that some of those, Older adults included also had comorbidities like hypertension, diabetes, chronic pulmonary disease.So they really did make efforts to try to get individuals who would be more representative of our older adults. I don't think though that any nursing home patients were included.

At least there are, there's no indication that they did. And so the testing in that population, I think has been very limited in both the Pfizer and the Moderna treatmentsMarshall. Why is it so important to specifically study those in nursing homes, if you're looking at the age cohort that nursing home residents include?.

Inouye. The hardest hit venue in terms of proportion of severe illness from erectile dysfunction treatment and death has been in our long-term care facilities in our country. That is a targeted priority group as identified by multiple expert panels and advisory groups, and they are being targeted in phase one of the treatment release effort.I think everyone would agree.

It would have been beneficial if there, if there had been more testing in that population prior to the release.Marshall. When you look at that age group, what we heard a lot about at the different committee meeting hearings on these two different treatments where you could extrapolate the data and have it represent those older Americans pretty well. Is that not really the case or are there different reasons that that older group needed to be a more robust number in these clinical trials?.

Inouye. That's a really good question. Serena.

I do think that the population in long-term care facilities tends to have more comorbidities, meaning more chronic diseases. They're on more medications. A lot of times there's a high prevalence of cognitive and functional decline.

And also we know from other types of vaccination studies that the immune response may be less robust than in younger populations are, or even the same age populations that are not in a nursing home.And so yes, to test both the efficacy of the treatment and potential side effects of the treatment in that population would have been helpful, I believe, but I think you can still extrapolate that the treatment will have some effectiveness. I think it's just not clear how robust that will be exactly.And also the, what the exact side effect profile might be.Marshall. As a geriatrician, does it concern you that there's still so much we don't know about that specific cohort these different treatments?.

Inouye. Yes. Well, I wear two different hats and as a geriatrician, yes, it does really concern me, and I think about it all the time and patients are asking me, should I get it?.

I'm not sure I feel totally comfortable that it's been adequately tested. And my response is influenced by several factors.First, is that in any kind of treatment or treatment trial, you have limitations in what you can accomplish, right?. In the clinical trials, there's always that limitations.

And even with the flu treatments that we're very used to giving to this population every year. The individual flu treatments each year are not robustly tested in the nursing home population either.And so that's not unusual. And similarly for other treatments, they're not always tested in older adults before they're released to the market.Marshall.

Why is that?. Inouye. I think it's the case because, frankly, there, there is some degree of age-ism in our country, and that population can be more challenging and difficult to study and can delay your procedures.

It can be more expensive and there can be more side effects. And so I think, obviously if you're a drug developer and you're trying to develop something quickly and you want it to have the least side effects, then you are going to shy away from that population.And there's been a lot written about this in terms of cancer drugs, and cardiac drugs, and a lot of other treatments that are primarily the largest audience, the largest target population is older adults that the testing hasn't been adequate in the past. And the National Institutes of Health has even created a new policy that older adults must be included in any trials that are funded by them.Marshall.

That's interesting. That's a new policy?. Inouye.

It went into effect at the beginning of 2019, so fairly new.Marshall. Quite shocking. It's taken us this long to have that as a necessity.Inouye.

Exactly, exactly. And so that's still an issue. And I think it's both logistical, but also I think there is an attitude that it's not necessary to include older adults.

And that's what I'm really trying to fight against.Marshall. But how do you drum up interest in getting more older adults to want to participate in clinical trials?. Inouye.

So there is huge interest amongst older adults in participating. And in fact, I had hundreds of people reach out to me after one of my articles came out about "how do I get into a trial or, I volunteered and I was turned down." I can't tell you how many times I heard that. Just an outpouring of interest.

And, I think a lot of it depended on how physically close you lived to a clinical trial site and then just the strategy by which they were doing outreach. But I think a lot of older adults were very, very willing to participate.I run studies and trials in the over 70 population and it's just amazing how much that generation wants to contribute to science and to advancing healthcare and to leaving a legacy. And feel it's very important.

They feel it's part of their mission. And I did want to say that I do think that's another reason why older adults would be willing to get the treatment, because I do think many of them feel it's their public duty.Marshall. Is that a different way of thinking one generation to the next?.

Inouye. I think so. I mean, I see it very much in that older generation and I think it's a different mindset, right?.

This was the same generation though, that lived through World War 2 and was used to doing things for the country and, do a lot of self sacrifice for the sake of the country.And I kind of feel like that attitude has been lost in our country.Marshall. You said though that a lot of them were turned away from the clinical trial, but it seemed that they were having trouble enrolling that age group. So what is the juxtaposition there?.

Inouye. It's similar to what I wrote up in my paper in JAMA Internal Medicine, that many of the trials had what I consider to be ageist, exclusionary criteria criteria that were unjustifiably, excluding older adults, like requiring that they communicate by text messaging, requiring that they have Wi-Fi at home that they were using regularly, that they would respond to immediate messages on their Wi-Fi.You know, and that just, why can they call them on the phone?. I'm not sure that's why these particular patients were excluded, but there were also other criteria that didn't seem well justified, like very well controlled, mild comorbidities.

Didn't seem like a justifiable exclusionary criteria. Maybe they had trouble with their vision or their hearing and that should be something you could adapt to and should not be an exclusionary criteria, but it was from some of the studies that we found. There's no reason from a medical standpoint, right.

That, that should be an exclusion.Marshall. You would think that nursing home residents might be an easy group to include in a clinical trial because you have somebody there who's essentially monitoring their vitals and their wellbeing on a day-to-day basis.Inouye. Yup.

Yup. I totally agree.Marshall. That's not the case?.

Inouye. It's not the case because I think they're viewed as high risk. You may need to get proxy consent, meaning from a family member.

And so it takes extra time. But I think the reality is the concerns that your results may not look quite as good, right, in that population. And so it may slow down your time to approval.Marshall.

So you're saying because they have more comorbidities or have other factors that would play into how they received the treatment, they might not be giving the clinical trial the results they're looking for?. Inouye. Right because their immune response may be a bit less robust.

And so they may get more s despite the treatment. And then there may also be more side effects.Marshall. One would think that you would want to know those things before mass distribution of a product.Inouye.

One would think so. I agree, but I think that you can understand if you were on the side of expediency, right. That it may slow you down.

It may make your results look worse and so...Marshall. So we wouldn't be seeing that 95% efficacy.Inouye. We may not.

You can call it age-ism or you can call it expediency. I would have wanted it tested in that population and I would have liked to see the results in that population.But again, that's rarely done with any treatment before it's released.Marshall. What are you seeing as some of the major concerns?.

Among older adults ....caregivers for older adults when it comes to getting the treatment?. Inouye. Well, I'm hearing a lot that.

"This has been so rushed. Are we sure it's okay?. Are we sure it's safe?.

Has it been adequately tested?. Do we know that it works?. Do we know it's not going to have side effects?.

"Marshall. Those are a lot of the same questions we're hearing among younger...Inouye. ...everybody, right?.

Yes. I think it's all the same concerns and. And I totally validate where those questions are coming from.

We have to admit that this project Warp Speed and all of these treatments have been developed in an amazing process and amazing burst of incredible science, frankly, it's a miracle.But I think the best science has gone into it. The testing has been there. I think everything has been done according to strict guidelines and standards.

As soon as my number is called, I'm going to be in line to get it. And I have a 91 year old mother. We are all firmly united that the risks to my mother of getting erectile dysfunction treatment are so much higher then the risks of side effects that could be serious, but we know are going to be rare.But it's a gamble that where, I think the equation is definitely in favor of getting the treatment.Marshall.

When you look at some of the public prominent figures who we've seen getting the treatment, some of the prominent older celebrities, or even politicians. Does that play a role in helping alleviate some of the concerns specifically among this subgroup who in some cases were alive during the polio treatment. Saw the Elvis push -- does that play a key role in maybe helping them decide to get it or not?.

Inouye. I think it does raise confidence. I think when they see, people they admire and respect and trust getting the treatment...I mean, it reassures me right, when Tony Fauci gets the treatment, then I know like, I'm okay.

He's my hero.This is really going to change the equation in our favor in favor of humankind. Once we can get everybody vaccinated.Marshall. When we look at this treatment, there's two doses.

How do you ensure uptake among this group of getting both doses?. They might go in for the first and then the pain and the discomfort, dissuade them from following up with the second.Inouye. Yeah, I think in the long-term care setting, that's easier to control because they're there in the facility.

If it's someone who has to go back. I don't know exactly what healthcare professionals or like if it's through CVS or Walgreens, I'm sure there are reminder systems and follow-ups.I am hoping that people will get the second one because definitely, to go through the first one and not then make sure you have adequate immunity. It's sort of like going through the pain and not getting the gain.

And so I hope people will be willing to get both.The side effects, they can be uncomfortable, no question. The painful arm and the flu-like syndrome for a day or two.But, you know, those are signs that it's working and probably similar to other treatments that people have received.Marshall. I want to come back to that question of age-ism.

There was some debate when discussing who should get the treatment and in what order .... Essential workers versus elder Americans more broadly, not talking about those nursing home residents. Now we know older Americans are more susceptible to erectile dysfunction treatment.We talked about how they have more comorbidities in some cases related to their age, but then there's the question of the essential workers and the need to get the economy back up and running.

This is definitely an ethical question, but is it one that ultimately... Does it come down to the question of age-ism?. Inouye.

Yeah. It's a really good question. I campaigned very hard for older adults to be included in that phase one.

And older adults with comorbidities are included in that phase one. So that is the highest risk population in older adults as well in the facilities.I think in part, it may have been influenced by age-ism, but also in part just by practicality. Right?.

You know, you're only going to have a limited amount of treatment early on, and it is, I do agree. It's really important to have frontline healthcare workers, for instance, protected because they can also spread it, right?. Amongst many others, other patients who were very ill and then also that the staff in facilities, as well.

In fact, I don't know the exact percentage, but it's been well-documented that many of the outbreaks in long-term care facilities are initiated or propagated by staff. And so I think that's really important that staff in long-term care facilities be in that first group, which they are.And so I think that will help both with spread and curtailing the . I mean, ideally what we're hoping is everyone, right.

Will be able to be vaccinated within a few months, ideally by the late spring. Definitely by the fall, it's projected that there will be enough for everyone who wants to get vaccinated to be vaccinated.Marshall. So, looking at this specific age cohort....Where do we go from here?.

What have these treatment trials for erectile dysfunction treatment taught us when it comes to elder inclusion in clinical trials more broadly?. Inouye. I honestly thought a better job would be done.

That's really what I had hoped for because of knowing that, the population so affected with erectile dysfunction treatment was so disproportionately skewed to older adults. I thought this has gotta be the point at which this will change. This, this has gotta change it.And in reality, I mean, some efforts were made, right.

The age range in the Pfizer trial was 75 to 91. So there were efforts made to include people, in their eighties and even someone 91. So that's incredible.

But, as we pointed out at the beginning, it was less than 4% right. Of the overall trial population.So, that was disappointing. Very small icing on the cake.

It just wasn't a genuine effort.Marshall. So, did we learn anything as a society then?. Inouye.

I don't know....I haven't heard a loud public outcry about it, which was disappointing. I had hoped that would happen. I think, when I talk to people working at the FDA about this, they also acknowledge this.

They also predicted that there wouldn't be very many included and that the argument was going to be well, this will all be testing, tested in post-marketing surveys, which is how most of the product testing happens in older adults.After approval in what's called post-marketing surveillance. And, I had hoped this would be different in that, because of the demographics of erectile dysfunction treatment that we could make it different. And so I'm hoping to continue to use this as an example, and as a platform for maybe changing things in the future.I think people are stepping up and speaking out for our older population, but it's going to take a while to make these major changes happen, right?.

And there's going to need to be policy change and regulation change. And I was so disappointed when the FDA did not require older adults, a certain proportion to be enrolled.That's what I was so hoping would happen. And they did not require it.

It was a recommendation, but no stronger than that. And that's where we need to change things. It needs to happen at a policy level.

And so I'm hoping over the course of time and with what we've seen here, what we've learned, what we've shown, that we can start to make those changes happen at the policy level.Marshall. I hope that you'll keep us updated on how those policy changes go as you continue to push forward on this issue. Thank you so much for joining us here at "Track the Vax." One of the last questions we love to ask everyone.

I know you mentioned it earlier, when it's your turn in line, you do plan to get the treatment?. Inouye. I do hope to get the treatment.

The system crashed at my hospital because of too many healthcare professionals wanting to sign up all in the same day. So, I decided to wait a little while longer to sign up.I don't work in the emergency room or in the intensive care units. So, I'll probably be in the...

I'll definitely be able to get it, but I don't know exactly when. But I'm hoping to be able to get it soon.Marshall. Well, good luck.

And thank you again for your time.Inouye. Okay. Thank you so much.